TIM Gastrointestinal Model: A Predictive Powerhouse for Bioaccessibility and Drug Development

Abstract

This article provides a comprehensive overview of the TNO Gastro-Intestinal Model (TIM), a dynamic in vitro system that accurately simulates human digestive processes. Tailored for researchers and drug development professionals, we explore the foundational principles of TIM systems, including TIM-1, tiny-TIM, and the advanced gastric compartment (TIM-agc). The content details methodological protocols for assessing drug bioaccessibility under various physiological conditions, addresses common challenges and optimization strategies, and presents extensive validation data comparing TIM outcomes with human clinical results. By synthesizing evidence from recent studies, this article positions TIM as an indispensable, ethically favorable tool for predicting nutrient and drug bioavailability, ultimately enhancing the efficiency and success rate of pharmaceutical development.

Understanding the TIM System: Core Principles and Physiological Relevance

What is the TIM Model? Introducing the Multi-Compartmental Dynamic System

The TNO Gastro-Intestinal Model (TIM) is a sophisticated, multi-compartmental, dynamic system designed to realistically simulate the physiological conditions within the human gastrointestinal tract [1]. Developed in the early 1990s by TNO (The Netherlands Organisation for Applied Scientific Research) in response to industrial demand for more physiologically relevant digestion models, these computer-controlled systems simulate the stomach, small intestine, and large intestine with high precision [1] [2]. TIM systems are invaluable tools for studying the digestibility of food, the bioaccessibility of nutrients and pharmaceuticals, and the release of active compounds from various formulations [2]. The core principle of TIM is to combine the controllability and reproducibility of a laboratory model with dynamic physiological parameters such as peristaltic mixing, transit times, secretion of digestive fluids, regulation of pH, and removal of digestion products [1].

A key output from TIM experiments is bioaccessibility, defined as the fraction of a compound that is released from the food matrix and becomes available for absorption through the gut wall [3]. This is distinct from bioavailability, which refers to the amount of an ingested nutrient that is actually absorbed and becomes available for physiological functions [3]. TIM systems primarily measure bioaccessibility, and when these results are combined with additional intestinal cell assays or in silico modeling, they can show high predictability for human in vivo data [1] [4].

The TIM platform consists of several configurations, each designed for specific research applications. The following table summarizes the primary models and their characteristics.

Table 1: Key Configurations of the TIM Systems

Model Name	Compartments Simulated	Key Features	Primary Applications
TIM-1 [1]	Stomach, Duodenum, Jejunum, Ileum	Four connected compartments; realistic meal transit; dialysis/filtration for absorption	Study of macro/micronutrient digestibility, drug release, and bioaccessibility in the upper GI tract
TinyTIM [1]	Stomach, Single Small Intestinal Compartment	Simplified, higher-throughput version; single intestinal compartment with no ileal efflux	Screening studies where separate intestinal steps are not critical
TIM-2 [2]	Large Intestine (Colon)	Contains human microbiota; simulates fermentation	Study of colonic fermentation, prebiotics, probiotics, and colon-targeted drugs
TIM-agc [1]	Advanced Stomach	Mimics shape and motility of the stomach; simulates antral waves and pyloric sphincter opening	Investigating the effect of gastric motility on food and drug behavior
TIMpediatric [5]	Stomach & Small Intestine (Pediatric)	Simulates age-specific GI conditions for neonates, infants, and toddlers	Pediatric drug and nutrition research, avoiding ethical constraints of clinical studies

Applications and Experimental Findings

The TIM systems are extensively used in nutritional and pharmaceutical sciences to generate highly predictive data for the human situation [4]. Below is a summary of quantitative results from selected studies.

Table 2: Example Applications and Results from TIM Studies

Study Focus	Experimental Setup	Key Result (Bioaccessibility)	Significance
Protein Quality [6]	TIM-1, fast GI transit	Salmon Protein Hydrolysate (SPH): 67.0%Extensively Hydrolyzed Whey Protein (WPH-High): 56.0%Whey Protein Isolate (WPI): 38.5-42.2%	SPH provides more bioaccessible nitrogen, valuable for medical foods requiring rapid protein uptake.
Fat & Cholesterol [7]	TIM-1, high-fat meal protocol	Partially Hydrolyzed Guar Gum (PHGG) decreased the bioaccessibility of fat and cholesterol in a dose-dependent manner.	Demonstrates the utility of TIM for screening functional food ingredients.
Drug Formulation [8]	TIM-1 & in silico modeling	TIM-1 data used with PBPK modeling accurately described dissolution and precipitation of a weakly basic drug (PF-07059013).	Shows how TIM can support drug product design and provide a biopredictive assessment of performance.
Pediatric Drug Delivery [5]	TIMpediatric	Studied bioaccessibility of paracetamol and diclofenac with age-related food and co-medication (esomeprazole).	Provides a validated tool to study pediatric dosing without ethical constraints of clinical trials.

Detailed Experimental Protocol: Protein Digestibility in TIM-1

The following is a generalized protocol for assessing protein digestibility and nitrogen bioaccessibility, based on studies such as the one comparing salmon and whey proteins [6].

Research Reagent Solutions

Table 3: Essential Reagents for a TIM-1 Protein Digestibility Experiment

Reagent / Component	Function in the Experiment
Artificial Saliva [1]	Contains electrolytes and α-amylase; initiates starch digestion during the oral phase.
Gastric Secretion [1]	Contains electrolytes, pepsin, and a fungal lipase; simulates the digestive environment of the stomach.
Duodenal Secretion [1]	Contains electrolytes, bile, and pancreatin; provides enzymes and bile salts for intestinal digestion.
Hydrochloric Acid (HCl) [1]	Used to dynamically control the pH in the gastric compartment according to a pre-set curve.
Sodium Bicarbonate (NaHCO₃) [1]	Used to neutralize acidity and control the pH in the intestinal compartments.
Dialysis Membranes [1] [6]	Connected to jejunal and ileal compartments with a molecular weight cutoff (e.g., 10 kDa); allow removal of water-soluble digestion products (e.g., peptides, amino acids) representing the bioaccessible fraction.

Workflow and Procedure

The diagram below illustrates the key stages of a typical TIM-1 experiment.

Step 1: System Initialization and Meal Preparation

• Set the TIM-1 system parameters to the desired protocol (e.g., adult fasted state, or fed state with a specific meal type) [1]. This includes setting the body temperature (maintained at 37°C), gastric and intestinal transit times, and secretion rates.
• Prepare the test meal. For solid foods, masticate using a food processor and mix with artificial saliva [1]. For protein powders or hydrolysates, the substrate is mixed with the liquid meal or water relevant to the experiment [6].

Step 2: Gastric Digestion

• Introduce the meal into the gastric compartment.
• The computer system initiates the dynamic simulation: gastric secretion (containing pepsin and lipase) is added, and the pH is continuously measured and controlled by adding HCl to follow a predetermined curve [1].
• The gastric content is mixed by alternating pressure on the flexible walls of the compartment, simulating peristalsis.
• Gastric emptying is controlled according to physiological formulas, transferring chyme to the duodenum compartment at a controlled rate [1].

Step 3: Small Intestinal Digestion

• In the duodenum, jejunum, and ileum compartments, chyme is mixed with duodenal secretion (containing pancreatin and bile) [1].
• The pH in these compartments is maintained at pre-set values (typically increasing towards the ileum) by the addition of sodium bicarbonate [1].
• As digestion proceeds, the products (such as peptides and amino acids from protein) are released from the food matrix.

Step 4: Absorption Simulation and Sampling

• The bioaccessible fraction is defined as the compounds that pass through the dialysis membranes connected to the jejunal and ileal compartments [1] [6]. These membranes have a specific molecular weight cutoff (e.g., 10 kDa), allowing small, soluble compounds to be removed, mimicking passive absorption [1].
• The dialysate from the jejunum and ileum is collected at regular intervals (e.g., every 15-30 minutes) over the course of the digestion (e.g., 2 hours) [6].
• Additionally, samples can be taken directly from the lumen of each intestinal compartment to analyze the distribution of compounds during transit [6].

Step 5: Data Analysis

• The nitrogen content in the dialysate samples (representing bioaccessible nitrogen from digested protein) is determined, for example, using the Kjeldahl method or Dumas combustion [6].
• Bioaccessibility is calculated as the cumulative amount of nitrogen in the dialysate expressed as a percentage of the total nitrogen introduced with the meal [6]. Results from different substrates can then be statistically compared.

The TNO Gastro-Intestinal Models (TIM) represent a pinnacle of in vitro simulation technology, offering a highly controlled, reproducible, and physiologically relevant platform for studying the complex processes of digestion and absorption. With its various configurations, TIM can be adapted to simulate conditions in different species, age groups, and physiological states. The integration of TIM data with mucosal transit assays and in silico kinetic modeling has been shown to provide highly predictive information for human bioavailability, potentially reducing the need for animal studies and increasing the success rate of subsequent human trials [4]. As this technology continues to be refined and digitalized [8], its role in advancing food and pharmaceutical sciences is set to grow even further.

The human gastrointestinal (GI) tract represents a critical interface for the absorption of nutrients and oral drugs, yet its complex, dynamic physiology presents significant challenges for predicting bioaccessibility and bioavailability. Bioaccessibility, defined as the fraction of a compound that is released from its matrix and becomes available for intestinal absorption, is strongly influenced by dynamic GI parameters [9]. Traditional static in vitro models and simple dissolution apparatus fail to replicate the intricate interplay of physiological factors that govern digestion and absorption in vivo, often leading to poor predictive quality for human outcomes [10]. The TNO Gastrointestinal Model (TIM) systems have been developed as computer-controlled dynamic in vitro simulations that mimic the stomach, small intestine, and large intestine. These systems are designed to bridge the gap between conventional in vitro tests and human trials by incorporating essential GI parameters, thereby providing highly predictive information for the human situation [9]. This application note details the physiological basis of these dynamic models and provides structured protocols for their application in bioaccessibility research, framed within the broader context of a thesis on TIM technology.

Physiological Principles of GI Dynamics and Their Replication in TIM Systems

The predictive power of dynamic GI models rests on their ability to accurately simulate the key physiological processes of the human gut. The alimentary system is organized into specialized compartments—mouth, stomach, small intestine (duodenum, jejunum, ileum), and large intestine—each with distinct functions, separated by sphincters, and subject to complex regulatory feedback mechanisms [11]. The TIM systems replicate these compartments and their specific conditions.

2.1 Motility and Transit: GI motility involves both tonic and phasic contractions. Tonic contractions increase pressure in the proximal stomach and create haustral sacculations in the intestines, while phasic contractions result in rhythmic peristaltic waves that mix, grind, and propel content distally [11]. In TIM systems, this is simulated using computer-controlled rotary pumps that adjust water pressure outside flexible silicone walls, mimicking the squeezing action of the stomach and intestines [9] [10]. Transit times are carefully regulated to match human physiological data for fasted and fed states.

2.2 Digestive Secretions and pH Dynamics: The GI tract features time-dependent changes in pH and controlled secretion of digestive fluids (gastric acid, bile, pancreatic enzymes). These parameters are critically important for the dissolution and chemical stability of compounds. TIM systems use computer-controlled pumps to introduce realistic gastric and intestinal secretions at physiological rates and times [9]. The pH in each compartment is continuously monitored and adjusted to follow in vivo profiles, which is crucial for simulating the release of ionizable drugs and the activity of digestive enzymes.

2.3 Absorption and Fluid Dynamics: A key feature of TIM systems is the incorporation of dialysis or filtration units connected to the intestinal compartments. These units remove small molecules and water, simulating passive absorption across the intestinal mucosa and providing a direct measure of bioaccessibility [9]. Recent research highlights the significance of GI fluid dynamics, where fluid volume is determined by a balance between water absorption and secretion. This balance directly influences dissolved drug concentration and absorption kinetics [12]. Models that incorporate these real fluid fluxes provide a more accurate prediction of luminal drug concentrations.

Table 1: Core Physiological Parameters Simulated in TIM Systems

Physiological Parameter	In Vivo Reality	TIM Simulation Method
GI Motility & Transit	Phasic & tonic contractions; regulated emptying	Computer-controlled water pressure on flexible walls; peristaltic mixing
Luminal pH	Dynamic, time-dependent changes (fasted: stomach ~1.5-3, intestine ~6-7.5)	Continuous monitoring & adjustment via addition of acids/alkali [10]
Digestive Secretions	Gastric juice, bile, pancreatic enzymes, bicarbonate	Computer-controlled infusion at physiological rates & timing [9]
Absorption	Passive & active transport across intestinal mucosa	Dialysis membranes or filtration systems [9]
Temperature	Maintained at 37°C	Temperature-controlled water circulation [9]

Applications in Drug Development: A Case Study with Metformin

The utility of dynamic GI models is exemplified in assessing the food effect on drug products. A study using the Dynamic Human Stomach-Intestine (DHSI-IV) system, a model conceptually similar to TIM, investigated the release and bioaccessibility of metformin hydrochloride immediate-release (IR) and sustained-release (SR) tablets under simulated fasted and fed states [10].

The system successfully reproduced the dynamic in vivo GI environment, including pH profiles and gastric emptying patterns. The study found that a high-fat meal significantly delayed drug release from both IR and SR tablets. The bioaccessible fraction of metformin from IR tablets in the fed state was reduced to 76.2% of the fasted state value, while the SR tablets were less impaired (fed/fasted ratio of 95.5%) [10]. Using a convolution-based in vitro-in vivo correlation (IVIVC), the in vitro bioaccessibility data were converted to predicted plasma concentration profiles. The results showed good agreement with human pharmacokinetic data, accurately predicting parameters like C~max~, T~max~, and AUC [10]. This case demonstrates how dynamic models can de-risk formulation development and provide critical data for regulatory submissions on food effects.

Table 2: Summary of Metformin Bioaccessibility and Predicted PK Parameters in the DHSI-IV Model [10]

Parameter	Immediate-Release (Fasted)	Immediate-Release (Fed)	Sustained-Release (Fasted)	Sustained-Release (Fed)
Bioaccessible Fraction	Not explicitly stated	76.2% of fasted value	Not explicitly stated	95.5% of fasted value
Predicted C~max~ (ng/mL)	943.9 ± 25.7	Significantly reduced	Data not shown in excerpt	Data not shown in excerpt
Predicted T~max~ (h)	2.0 ± 0.4	Delayed	Data not shown in excerpt	Data not shown in excerpt
Predicted AUC~0-24h~ (ng·h/mL)	7090.7 ± 112.0	Not significantly different	Data not shown in excerpt	Data not shown in excerpt

Advanced Protocol: Investigating Food Effect on a Solid Oral Dosage Form

This protocol outlines the steps for using a TIM system to evaluate the effect of food on the bioaccessibility of a model drug, following the principles demonstrated in the metformin case study [10].

4.1 Research Reagent Solutions and Essential Materials Table 3: Key Reagents and Materials for TIM Experiments

Item Name	Function/Description	Physiological Relevance
Simulated Gastric Fluid (SGF)	Contains pepsin, sodium chloride; pH adjusted to ~1.6 (fasted) or higher (fed)	Replicates gastric digestion and acidic environment [10]
Simulated Intestinal Fluid (SIF)	Contains pancreatin, bile salts; pH maintained at ~6.5-7.4	Replicates pancreatic enzyme activity and micellar solubilization in duodenum/jejunum [10]
High-Fat Meal Substitute	Liquid meal with defined fat, protein, and carbohydrate content (e.g., Ensure Plus)	Standardized meal to create fed-state conditions (reduced gastric acidity, slowed emptying)
Dialysis Membranes	Semi-permeable membranes with specific molecular weight cut-off	Simulates passive absorption of dissolved compounds across intestinal mucosa [9]
Test Formulation	Immediate-Release or Sustained-Release tablet/capsule	The oral solid dosage form under investigation

4.2 Experimental Workflow The following diagram illustrates the key stages of the experimental protocol for a food effect study.

4.3 Step-by-Step Procedure

• System Configuration and Calibration:

  • State Selection: Define the physiological state to be simulated (e.g., fasted or fed). The model settings, including secretion rates, pH, and transit times, must be pre-programmed accordingly [9].
  • System Setup: Fill the stomach and small intestine compartments with the appropriate initial fluids (SGF for stomach, SIF for intestine). Calibrate all pumps for secretion, pH adjustment, and emptying. Connect and pre-rinse the dialysis system.

• Dose Administration and Experiment Operation:

  • Dosing: Introduce the test formulation (e.g., metformin tablet) into the gastric compartment. In the fed state, administer the formulation mixed with the high-fat meal substitute [10].
  • Run Initiation: Start the TIM program. The system will automatically simulate peristalsis, regulate temperature at 37°C, add digestive secretions at physiological rates, and adjust pH based on real-time sensors.

• Sampling and Analysis:

  • Sample Collection: At predetermined time points, collect samples from two key locations: (a) the dialysate (representing the absorbed fraction, i.e., bioaccessible drug) and (b) the luminal chyme (representing the total dissolved drug) [9] [10].
  • Analytical Quantification: Analyze all samples using a validated analytical method (e.g., HPLC-UV) to determine the drug concentration at each time point.

• Data Processing and Bioaccessibility Calculation:

  • Kinetic Profile: Plot the cumulative amount of drug appearing in the dialysate over time.
  • Calculation: The total bioaccessible fraction is calculated as the percentage of the administered dose recovered in the dialysate over the entire experiment duration [10].
  • IVIVC: For advanced predictions, the in vitro bioaccessibility time-profile can be used as an input for convolution in PBPK modeling software (e.g., GastroPlus) to predict the human plasma concentration-time profile [9] [10].

The Integration of In Vitro and In Silico Modeling

The combination of dynamic in vitro TIM data with in silico (computer) modeling creates a powerful tool for predicting human bioavailability. TIM provides high-quality input data on bioaccessibility, which is often the most variable and difficult-to-predict component of oral drug absorption [9]. This data can be integrated with physiological-based pharmacokinetic (PBPK) models, which simulate distribution, metabolism, and excretion, to predict full plasma concentration-time profiles [11].

Emerging research focuses on enhancing these models further. For instance, mechanistic digestion models (MDM) attempt to codify all known physiology from the literature into a predictive computational framework [11]. Another frontier is the integration of 3D Computational Fluid Dynamics (CFD) with machine learning. CFD can simulate complex local conditions (e.g., peristaltic mixing, villous structures), and these insights are used to "correct" simpler, faster 1D models, creating a more physiologically sound predictive system [13]. This multi-scale, multi-method approach represents the future of predictive GI science.

Dynamic GI models like the TIM systems are sophisticated tools grounded in a detailed replication of human gastrointestinal physiology. By simulating motility, secretions, absorption, and transit with high fidelity, they provide highly predictive data on the bioaccessibility of nutrients and drugs. The structured protocols and case studies presented here, such as the investigation of food effects on metformin tablets, demonstrate their practical application in de-risking drug development and optimizing formulations. When the bioaccessibility data generated by these validated in vitro models is used as input for in silico PBPK modeling, the result is a powerful, synergistic platform that can significantly reduce the need for animal studies, increase the success rate of subsequent human trials, and accelerate the development of safe and effective oral products.

The TNO Gastro-Intestinal Model (TIM) represents a sophisticated platform of dynamic, computer-controlled systems designed to realistically simulate the physiological conditions within the human gastrointestinal tract [1]. These systems were developed in response to industrial demand for more physiologically relevant models compared to contemporary digestion models, evolving from experimental lab setups into comprehensive cabinet systems that serve feed, food, and pharmaceutical industries [1]. TIM platforms simulate the dynamic conditions in the lumen of the gastrointestinal tract by combining controllability and reproducibility with critical physiological parameters including mixing, meal transit, variable pH values, realistic secretion of digestive fluids, and removal of digested compounds and water [1].

The primary endpoint of TIM experiments is the determination of bioaccessibility - the fraction of a compound available for absorption through the gut wall [1]. Results from TIM systems, whether used independently or combined with additional intestinal cell assays and in silico modeling, have demonstrated high predictability compared to in vivo data [1] [9]. These systems can be programmed to simulate various conditions including species (human, dog, pig, calf), age (infant, adult, elderly), pathological states, and meal-related parameters based on in vivo data [1].

TIM Platform Specifications and Comparative Analysis

Technical Specifications of TIM Platforms

Table 1: Comparative Technical Specifications of TIM Platforms

Parameter	TIM-1	TinyTIM	TIM-agc
Compartments	Stomach, duodenum, jejunum, ileum [1]	Simplified gastric + single small intestinal compartment [1]	Advanced gastric design with body + two antral units [1]
Mixing Mechanism	Alternating pressure on flexible walls [1]	Similar to TIM-1 gastric compartment [1]	Simulated gastric tone reduction + antral wave mixing [1]
Transit Control	Peristaltic valve pumps with gastric/ileal emptying formulas [1]	Plug flow assumption without ileal efflux [1]	Synchronized pyloric sphincter simulation [1]
Temperature Control	Water circulation outside flexible walls [1]	Similar to TIM-1 [1]	Similar to TIM-1 [1]
Primary Applications	Comprehensive nutrient digestion studies, pharmaceutical bioavailability [1]	High-throughput screening, formulation development [14]	Gastric motility effects, solid dosage forms, food behavior [1]

Table 2: Simulated Physiological Conditions in TIM Systems

Physiological Parameter	Simulation Method	Control Mechanism
pH Regulation	Pre-set values for each compartment [1]	HCl and NaHCO₃ addition controlled by computer [1]
Gastric Secretions	Electrolytes, pepsin, fungal lipase [1]	Programmable flow rates in time [1]
Intestinal Secretions	Electrolytes, bile, pancreatin [1]	Programmable flow rates in time [1]
Product Removal	Dialysis (water-soluble) + filtration (lipophilic) [1]	Membranes (10 kDa cutoff) + 50 nm filters [1]
Meal Transit	Gastric/ileal emptying formulas [1]	Computer-controlled peristaltic valve pumps [1]

System Architecture and Workflow

Detailed Experimental Protocols

Protocol for Protein Quality Assessment in TIM-1

Objective: Determine the bioaccessibility and quality of protein sources by measuring the availability of essential amino acids [1].

Preparation Phase:

• Meal Preparation: Process the test meal using a food processor (Solostar II, Tribest) to simulate mastication [1].
• Saliva Addition: Mix with artificial saliva containing electrolytes and α-amylase [1].
• System Initialization: Set TIM-1 parameters to appropriate physiological conditions (human adult, fed state) [1].

Simulation Phase:

• Gastric Digestion (0-2 hours):
  • Introduce meal into gastric compartment
  • Maintain pH curve specific to meal composition using HCl
  • Secretion of gastric fluids (electrolytes, pepsin, fungal lipase F-AP 15)
  • Apply standard mixing protocol via flexible walls

• Small Intestinal Digestion (2-5 hours):
  • Control transit to duodenum using peristaltic valve pumps
  • Maintain duodenal pH with sodium bicarbonate
  • Secretion of duodenal fluids (electrolytes, bile, pancreatin)
  • Continue transit through jejunum and ileum compartments

Sampling and Analysis:

• Dialysate Collection: Collect fractions from jejunal and ileal dialysis systems at predetermined time points [1].
• Nitrogen Quantification: Determine protein nitrogen in dialysate using appropriate analytical methods (e.g., Kjeldahl, Dumas) [1].
• Amino Acid Analysis: Perform HPLC analysis of essential amino acids in collected fractions [1].
• Bioaccessibility Calculation: Express dialyzed protein nitrogen as percentage of protein nitrogen in initial meal, corrected for secreted protein [1].

Protocol for Pharmaceutical Formulation Testing in TinyTIM

Objective: Evaluate the bioaccessibility of poorly water-soluble drugs from different formulations under various prandial states [14].

System Configuration:

• Compartment Selection: Utilize half-size gastric compartment and single small intestinal compartment based on study requirements [1].
• Parameter Setting: Program conditions for fasted or fed state based on target physiology [14].

Experimental Procedure:

• Fasted State Simulation:
  • Pre-equilibrate system with fasted state simulated gastric fluid (FaSSGF)
  • Introduce drug formulation with 240 mL aqueous medium
  • Apply fasted state gastric emptying profile

• Fed State Simulation:

  • Pre-equilibrate with fed state simulated gastric fluid (FeSSGF)
  • Co-administer drug with standardized meal (e.g., high-fat meal)
  • Apply fed state gastric emptying profile

• Sampling Strategy:

  • Collect samples from intestinal compartment filtration system at regular intervals
  • Analyze drug concentration using validated UHPLC methods [14]
  • Calculate bioaccessible fraction over time

Data Interpretation:

• Compare concentration-time profiles between formulations
• Determine effect of prandial state on bioaccessibility
• Correlate in vitro results with published in vivo data [14]

Advanced Gastric Motility Protocol

Objective: Investigate the effect of gastric motility patterns on drug release and food disintegration using TIM-agc [1].

System Calibration:

• Motility Pattern Selection: Choose appropriate motility pattern (fed or fasting state) [1].
• Pressure Profile Validation: Validate pressure profiles using smartpill technology [1].

Experimental Execution:

• Meal Introduction: Place test material in advanced gastric compartment
• Motility Application:
  • Apply gradual contraction of gastric body to simulate tone
  • Program antral wave movements for mixing
  • Synchronize pyloric sphincter opening with antral waves
• Continuous Monitoring: Track pressure profiles, pH changes, and temperature throughout experiment

Sample Analysis:

• Collect gastric effluents at predetermined time points
• Analyze particle size distribution of emptied chyme
• Compare results with those from standard TIM-1 system

Research Reagent Solutions

Table 3: Essential Research Reagents for TIM Experiments

Reagent Solution	Composition	Physiological Function	Application Notes
Artificial Saliva	Electrolytes, α-amylase [1]	Initial digestion of carbohydrates, bolus formation	Prepare fresh before each experiment; maintain enzymatic activity
Gastric Secretion	Electrolytes, pepsin, fungal lipase (F-AP 15) [1]	Protein digestion, lipid hydrolysis, pH reduction	Fungal lipase used as alternative to gastric lipase; pH controlled with HCl
Duodenal Secretion	Electrolytes, bile, pancreatin [1]	Emulsification of fats, nutrient digestion, pH neutralization	Bile concentration adjusted based on meal fat content
Dialysis Fluid	Isotonic electrolyte solution [1]	Simulation of serosal side absorption	Maintain physiological osmolarity; regular replacement recommended
Fasted State Gastric Fluid (FaSSGF)	Gastric electrolyte solution (GES) with low pH [14]	Simulation of fasted stomach conditions	Used for pharmaceutical testing in fasted state
Fed State Gastric Fluid (FeSSGF)	Enhanced electrolyte solution with nutrients [14]	Simulation of fed stomach conditions	Composition varies based on meal type being simulated

Data Integration and Validation Framework

The integration of TIM systems with additional analytical approaches significantly enhances their predictive power [9]. TIM bioaccessibility data combined with mucosal transit assays and published kinetic parameters can be used as input for in silico modeling to predict human bioavailability and plasma concentration profiles [9]. This combined approach has been validated against human studies for various nutrients and pharmaceutical compounds, demonstrating high predictive quality and offering the potential to reduce animal experiments and increase the success rate of subsequent human studies [9].

The TNO Gastro-Intestinal Model (TIM) is a sophisticated, multi-compartmental dynamic system designed to realistically simulate the physiological conditions within the human gastrointestinal (GI) tract [1]. By accurately replicating the dynamic environment of the gut lumen, TIM provides a powerful in vitro tool for predicting the bioaccessibility of nutrients, pharmaceuticals, and bioactive compounds [1] [15]. Bioaccessibility, defined as the fraction of a compound that is released from the food or product matrix and becomes available for absorption through the intestinal wall, is a critical endpoint for TIM experiments [1] [16]. The high predictive quality of TIM data for human in vivo outcomes has been repeatedly demonstrated through validation studies, making it a valuable asset for research and industry, potentially reducing the need for animal testing and increasing the success rate of subsequent human trials [15]. The reliability of this model hinges on the precise control and monitoring of four key physiological parameters: pH, transit times, secretions, and temperature. This application note details the protocols for controlling these parameters within the TIM systems to obtain physiologically relevant and highly predictive data for bioaccessibility research.

Key Controlled Parameters and Their Physiological Relevance

The TIM systems use computer-controlled simulations to mimic the dynamic conditions of the GI tract. The following parameters are essential for creating a biologically relevant environment.

pH

The pH within the GI tract is not static; it changes progressively both over time and in different anatomical locations. The TIM system actively controls pH using feedback systems to follow predetermined curves based on in vivo data [1].

• Gastric Compartment: The initial pH of the ingested meal is gradually acidified by the controlled secretion of hydrochloric acid (HCl) to simulate the acidic environment of the stomach [1].
• Intestinal Compartments: The acidic chyme entering the duodenum is neutralized by the controlled secretion of sodium bicarbonate (NaHCO₃) to simulate the pancreatic and biliary secretions, maintaining a pH gradient along the small intestine [1].

Table 1: Representative pH Parameters in TIM for an Adult Human (Fed State)

Compartment	Key Secretion for pH Control	Representative pH Profile/Setpoint	Citation
Stomach	Hydrochloric Acid (HCl)	Gradual acidification from meal pH to ~2-3 over time	[1] [17]
Duodenum	Sodium Bicarbonate (NaHCO₃)	Controlled at pre-set values (e.g., ~6-6.5)	[1]
Jejunum	Sodium Bicarbonate (NaHCO₃)	Controlled at pre-set values (e.g., ~6.5-7.5)	[1]
Ileum	Sodium Bicarbonate (NaHCO₃)	Controlled at pre-set values (e.g., ~7.5)	[1]

Transit Times

The rate at which food and chyme move through the GI tract is a critical factor influencing digestion and absorption. TIM accurately simulates this transit.

• Gastric Emptying: The emptying of the stomach compartment is controlled by peristaltic valve pumps and dictated by mathematical formulas, such as the one described by Elashoff et al. (1982), which is derived from in vivo data [1].
• Small Intestinal Transit: In the full TIM-1 system, chyme moves sequentially through the duodenum, jejunum, and ileum compartments. The transit is controlled to reflect the gradual passage through the small intestine [1]. The simplified TinyTIM system uses a single intestinal compartment where transit is simulated as a traveling plug of chyme [1].

Table 2: Transit Time Parameters in TIM Systems

Parameter	Description	Control Mechanism	Citation
Gastric Emptying	Dictated by a predetermined curve (e.g., Elashoff formula)	Peristaltic Valve Pumps (PVPs)	[1]
Ileal Emptying	Dictated by a predetermined curve	Peristaltic Valve Pumps (PVPs)	[1]
Small Intestinal Transit (TIM-1)	Gradual transit through three sequential compartments	Peristaltic Valve Pumps (PVPs) between compartments	[1]
Small Intestinal Transit (TinyTIM)	Simulated as a single traveling plug of chyme	Removal through a single filtration/dialysis membrane	[1]

Secretions

The TIM systems simulate the timed and regulated secretion of various digestive fluids, whose composition is based on physiological data.

• Secretory Fluids: The model incorporates the secretion of artificial saliva, gastric juice, bile, and pancreatic fluid [1]. The composition of these fluids includes electrolytes and enzymes relevant to each GI region.
• Flow Rates: The flow rates of all secretions are programmable over time, allowing for the simulation of different digestive phases (e.g., fasted vs. fed state) and conditions (e.g., infant, adult, elderly) [1].

Table 3: Composition of Secretions in TIM Systems (Adult Human)

Secretion	Key Components	Function in Digestion	Citation
Artificial Saliva	Electrolytes, α-amylase	Initiates starch digestion	[1]
Gastric Secretion	Electrolytes, Pepsin, Fungal Lipase (as alternative to gastric lipase)	Protein digestion and initial lipid digestion	[1]
Duodenal Secretion	Electrolytes, Bile, Pancreatin	Neutralization, emulsification of fats, and full nutrient digestion	[1]

Temperature

Maintaining a consistent, physiologically relevant temperature is fundamental for proper enzyme activity and realistic reaction kinetics.

• Control System: In TIM systems, temperature is maintained at 37°C by circulating temperature-controlled water outside the flexible walls of the compartments [1].
• Precision: Advanced miniaturized digestion systems have demonstrated the capability to control temperature with an accuracy of up to ±0.1°C, ensuring optimal and consistent enzymatic function [18].

Experimental Protocols

Protocol 1: General Setup and Operation of TIM-1 for a Fed State

This protocol outlines the standard procedure for operating the TIM-1 system to simulate the digestion of a meal in an adult human.

• System Initialization: Turn on the TIM-1 cabinet and the controlling computer. Initiate the water circulation system and set the temperature to 37°C. Allow the system to stabilize.
• Software Protocol Selection: Load a pre-defined "Fed State - Adult" protocol. This protocol contains the temporal profiles for gastric and ileal emptying, secretion rates of all digestive fluids, and the target pH curves for each compartment.
• Meal Preparation and Introduction:
  • Comminute the test meal (e.g., a high-fat meal) using a food processor to simulate mastication.
  • Mix the comminuted meal with a pre-defined volume of artificial saliva.
  • Introduce the meal/saliva mixture into the gastric compartment of the pre-warmed TIM-1 system.
• Initiation of Digestion: Start the computer-controlled simulation. The system will automatically:
  • Begin mixing in all compartments via alternating pressure on the flexible walls.
  • Initiate gastric acid secretion to follow the pre-set pH curve.
  • Start the gradual emptying of the gastric compartment into the duodenum.
  • Add duodenal secretions (bile, pancreatin, electrolytes) and control intestinal pH with NaHCO₃.
• Sample Collection: Throughout the experiment, samples can be collected from:
  • Dialysate: The dialysis fluid from the jejunal and ileal compartments, representing the bioaccessible fraction of compounds (water-soluble).
  • Filtered Fraction: The filtrate from the 50 nm filter in the ileal compartment, representing the bioaccessible fraction of lipophilic compounds incorporated in micelles.
  • Chyme: Directly from each compartment at specific time points for time-resolved analysis.
• Termination and Cleaning: At the end of the simulated digestion period (e.g., 4-6 hours), stop the simulation. Empty and thoroughly clean all compartments and tubing according to standard operating procedures to prevent cross-contamination.

Protocol 2: Studying Protein Digestibility and Amino Acid Bioaccessibility

This specific method details how to use TIM to evaluate the quality and digestibility of proteins.

• TIM Setup: Follow the general setup protocol (3.1) using a standardized meal containing the test protein.
• Sample Collection: Collect the dialysate from the jejunal and ileal compartments throughout the experiment. This dialysate contains the water-soluble digestion products, including small peptides and free amino acids.
• Analysis:
  • Total Nitrogen: Determine the amount of protein nitrogen in the dialysate samples using a standard method like the Kjeldahl or Dumas method.
  • Amino Acid Profile: Analyze the dialysate using HPLC or LC-MS to quantify the levels of individual essential amino acids.
• Data Calculation:
  • Bioaccessibility: Calculate the true protein digestibility by expressing the amount of protein nitrogen in the dialysate as a percentage of the protein nitrogen in the initial meal. This value is corrected for the nitrogen originating from the secreted enzymes [1].
  • Limiting Amino Acid: Identify the essential amino acid that is in shortest supply in the bioaccessible fraction relative to the human requirement, designating it as the limiting amino acid [1].

The Scientist's Toolkit: Essential Research Reagents and Materials

Table 4: Key Reagents and Materials for TIM Experiments

Item	Function / Role in Simulation	Citation
Artificial Saliva	Provides electrolytes and α-amylase to initiate starch digestion in the oral phase.	[1]
Gastric Secretion (with Pepsin)	Provides acidic environment and protease enzyme for protein digestion in the stomach.	[1]
Fungal Lipase (F-AP 15)	Serves as an alternative to human gastric lipase for the initial hydrolysis of dietary fats.	[1]
Duodenal Secretion (Bile, Pancreatin)	Neutralizes gastric acid and provides a suite of enzymes (proteases, lipases, amylases) and bile salts for fat emulsification.	[1]
Dialysis Membranes (10 kDa MWCO)	Mimics absorption by removing water-soluble digestion products (e.g., sugars, amino acids) in the small intestine.	[1]
50 nm Filtration System	Removes lipophilic digestion products incorporated into mixed micelles, simulating their absorption.	[1]
Hydrochloric Acid (HCl)	Used for the controlled acidification of the gastric compartment to simulate stomach pH.	[1]
Sodium Bicarbonate (NaHCO₃)	Used for the controlled neutralization of chyme in the intestinal compartments.	[1]
Peristaltic Valve Pumps (PVPs)	Enable the controlled transfer of chyme between compartments, simulating gastric and intestinal transit.	[1]

The precise and independent control of pH, transit times, secretions, and temperature is the cornerstone of the TIM system's ability to reliably simulate human gastrointestinal physiology. The detailed protocols and parameters provided in this application note serve as a guide for researchers to design and execute robust in vitro digestion studies. By adhering to these standardized yet adaptable methods, scientists in food, feed, and pharmaceutical development can generate highly predictive bioaccessibility data, thereby strengthening the rationale for product formulation and reducing the ethical and financial burdens of animal and human trials.

Bioaccessibility is defined as the proportion of a dietary bioactive compound or nutrient that is released from its food matrix and becomes soluble in the gastrointestinal tract, thereby becoming available for potential intestinal absorption [19]. This concept serves as a critical link between food consumption and bioavailability, which refers to the fraction of an ingested compound that ultimately reaches systemic circulation and is delivered to target tissues [20] [19]. The evaluation of bioaccessibility is therefore essential for accurately predicting the nutritional value and health benefits of functional foods, dietary supplements, and pharmaceutical formulations.

Within the framework of gastrointestinal research, the TNO Intestinal Model (TIM) systems represent sophisticated dynamic in vitro platforms that simulate human digestive processes with high physiological relevance [21]. These models are particularly valuable for bioaccessibility studies because they can replicate the dynamic conditions of the human GI tract, including temperature, pH gradients, gastric emptying rates, peristaltic movements, and secretion of digestive fluids [22] [21]. The TIM-1 system, which comprises the stomach, duodenum, jejunum, and ileum, allows researchers to monitor the progressive release of bioactive compounds throughout the upper gastrointestinal tract and collect samples for analysis at different digestive stages [21].

Experimental Workflow for Bioaccessibility Assessment Using TIM Models

The following diagram illustrates the comprehensive workflow for evaluating compound bioaccessibility using the TIM gastrointestinal model, encompassing sample preparation, dynamic digestion, fraction analysis, and data interpretation.

Detailed Methodologies for Bioaccessibility Experiments

TIM-1 System Operational Protocol

Apparatus Setup and Calibration

• Initialize the TIM-1 system (InnoGI Technologies) consisting of four sequential compartments: stomach, duodenum, jejunum, and ileum [21].
• Set the temperature control unit to maintain 37°C throughout the system using circulated water jackets.
• Calibrate peristaltic pumps for gastric juice, bile, pancreatic juice, and electrolyte secretions according to standardized physiological rates.
• Program the computer-controlled pressure system to generate simulated peristaltic waves (antral contractions: 3 waves/min; pyloric opening: controlled emptying) [21].
• Validate pH electrodes in each compartment and set point for automatic titration: stomach (initially pH 5.0, decreasing to pH 2.0-3.0), duodenum (pH 6.0-6.5), jejunum/ileum (pH 6.5-7.2) [21].

Digestion Parameters and Sampling

• Introduce the test sample (typically 10-50 g food or drug formulation) mixed with simulated saliva into the gastric compartment.
• Initiate the digestion process with continuous addition of simulated gastric juice (pepsin, HCl, NaCl) at 2.5 mL/min for the first 2 hours.
• After 30 minutes, begin duodenal delivery of pancreatic-biliary fluids (pancreatin, bile salts, bicarbonate) at 1.5 mL/min.
• Collect bioaccessible fractions from the jejunal and ileal compartments using semi-permeable membranes (50-100 kDa molecular weight cut-off) at 15-30 minute intervals.
• Maintain physiological transit times: gastric emptying (2-4 h), small intestine transit (4-6 h) adjusted based on meal composition [21].

Bioaccessibility Calculation Method

The bioaccessibility of target compounds is quantified using the following standardized calculation:

Bioaccessibility (%) = (Cbioaccessible / Cinitial) × 100

Where:

• C_bioaccessible = Concentration of compound in the absorbable fraction (usually jejunal/ileal dialysate)
• C_initial = Initial concentration of compound in the test sample before digestion

For bound compounds that require release during digestion (e.g., ferulic acid in cereal matrices), the calculation may be modified to account for the conversion from bound to free form [20].

Quantitative Bioaccessibility Data from Food Matrices

Table 1: Bioaccessibility of Bioactive Compounds from Various Food Matrices Following In Vitro Digestion

Food Matrix	Bioactive Compound	Processing Method	Bioaccessibility (%)	Key Findings	Reference
Triticale bran	Ferulic acid	Boiling	~65-75% (estimated)	Highest absorption in aging models; outperformed steaming & baking	[20]
Broccoli	Phenolic compounds	Fresh, steamed	35-40%	Significant losses during digestion; thermal treatment affects stability	[23]
Broccoli	Vitamin C	Fresh	<10%	Extreme sensitivity to digestive conditions	[23]
Spondias fruit co-products	Total phenolics	Ultrasonic extraction	Varies by compound: Epicatechin gallate: 135.5%Catechin: 106.6%Gallic acid: 108.5%	Increase due to release from matrix during digestion	[24]
Apple	Polyphenols	Fresh	60% reduction in aging model	Age significantly impacts bioaccessibility	[20]

Table 2: Impact of Thermal Processing on Bioaccessibility of Ferulic Acid in Triticale Bran

Thermal Treatment	Free Ferulic Acid Content	Bound Ferulic Acid Release	Antioxidant Capacity Retention	Bioaccessibility in Aging Model
Boiling	Significant increase	High	High preservation in GI tract	Highest absorption enhancement
Steaming	Moderate increase	Moderate	Moderate retention	Moderate improvement
Baking	Moderate increase	High	Variable retention	Less effective than boiling
No treatment (raw)	Baseline	Low	Baseline	Lowest absorption

The Scientist's Toolkit: Essential Research Reagents and Materials

Table 3: Key Research Reagent Solutions for TIM Bioaccessibility Studies

Reagent Solution	Composition	Physiological Function	Application Notes
Simulated Gastric Fluid	Pepsin (3 g/L), NaCl (7.30 g/L), KCl (0.52 g/L), NaHCO₃ (3.78 g/L), HCl to pH 2.5-3.0	Protein digestion in stomach	Add progressively to mimic gastric secretion; activity validated using hemoglobin assay
Simulated Intestinal Fluid	Pancreatin (1 g/L), bile salts (1.5 g/L), NaCl (1.27 g/L), KCl (0.23 g/L), NaHCO₃ (0.64 g/L), pH 8.0	Fat and carbohydrate digestion, micelle formation	Critical for hydrophobic compound bioaccessibility; prepare fresh daily
Dialysis Membranes	Cellulose esters, 50-100 kDa MWCO	Separation of bioaccessible fraction	Simulates intestinal absorption barrier; requires pre-conditioning
Standard Digestive Electrolytes	KCl, KH₂PO₄, NaHCO₃, NaCl, MgCl₂, (NH₄)₂CO₃	Maintain osmotic balance and ionic strength	Follow INFOGEST standardized concentrations for reproducibility
Antioxidant Preservative Cocktail	BHT, ascorbic acid, EDTA	Prevent oxidative degradation of bioactives	Add to collected fractions immediately; concentration depends on analyte sensitivity

Factors Influencing Bioaccessibility Measurements

Compound-Specific Characteristics

The chemical structure and properties of bioactive compounds significantly impact their bioaccessibility. Ferulic acid in triticale bran exemplifies how molecular binding affects release, as it exists primarily bound to arabinoxylan and other cell wall polysaccharides that resist digestion [20]. The stability of compounds during gastrointestinal transit varies considerably; vitamin C shows extreme sensitivity with over 90% degradation during digestion, while certain phenolics like epicatechin gallate may demonstrate apparent bioaccessibility exceeding 100% due to increased extraction from the matrix during digestive processes [24] [23].

Food Matrix and Processing Effects

The food matrix structure plays a decisive role in compound bioaccessibility. Thermal processing methods differentially influence bioaccessibility outcomes, with boiling demonstrating particular effectiveness for enhancing ferulic acid absorption from triticale bran, especially in aging populations [20]. Mechanical disruption through processing techniques like ultrasonic-assisted extraction can significantly improve bioaccessibility by breaking down cell walls and enhancing compound release [24]. The interaction between food components must also be considered, as macronutrients (proteins, carbohydrates, lipids) can bind bioactive compounds and either protect them from degradation or limit their release [19].

Physiological and Model Considerations

Age-related physiological changes significantly impact bioaccessibility, with reduced phenolic release observed in simulated aging conditions compared to young adult conditions [20]. The TIM model accounts for such variations through adjustable parameters including gastric emptying rates, enzyme secretion levels, and pH profiles tailored to specific population groups [21]. Validating in vitro bioaccessibility findings with absorption studies using Caco-2 cell models or Ussing chambers provides critical translation to biological relevance, as demonstrated in ferulic acid transport research [20].

Practical Guide: Applying TIM for Bioaccessibility and Food Effect Studies

Within gastrointestinal research using the TNO Gastro-Intestinal Model (TIM), the physiological state of the system—fasted or fed—is a critical experimental variable. This protocol details the standard operating procedures for configuring and executing fasted and fed state simulations within the TIM platform to study the bioaccessibility of nutrients and active pharmaceutical ingredients (APIs). The TIM is a multi-compartmental, dynamic, computer-controlled system designed to realistically simulate the dynamic conditions within the human gastrointestinal tract [9] [1]. Accurate simulation of these states is paramount for generating predictive data on compound availability for absorption, thereby strengthening experimental conclusions and their relevance to human physiology.

Defining Fasted and Fed States in the TIM System

In the context of the TIM, the "fasted state" refers to the simulation of gastrointestinal conditions in an individual who has not consumed food for several hours (typically 10-12 hours overnight). Conversely, the "fed state"模拟个体进食后的胃肠道条件。The choice between these states directly influences key physiological parameters controlled by the TIM software, including gastric emptying rates, secretion of digestive fluids, lumen pH, and transit times [9] [1]. These differences, summarized in Table 1, ultimately determine the release, dissolution, and bioaccessibility of the compound under investigation.

Table 1: Key Physiological Parameters for Fasted vs. Fed State Simulations in the TIM-1 System (Adult Human)

Parameter	Fasted State Simulation	Fed State Simulation	Technical Reference in TIM
Gastric pH	Initially low (~1.5-2.0), may increase slightly upon introduction of dosage form [10].	Higher initial pH (~5.0-6.0) due to meal buffering, gradually decreases [10].	Controlled by computer-activated addition of HCl [1].
Gastric Emptying	Rapid and continuous; often modeled with a power exponential function [1].	Slower, lag phase often present, followed by linear emptying [1].	Dictated by the gastric emptying curve programmed into the system [9].
Secretory Fluids (Bile, Pancreatin)	Lower flow rates [10].	Significantly increased flow rates stimulated by the presence of food [10].	Flow rates of secretions are programmable in time via the computer system [1].
Small Intestinal Transit Time	~4-5 hours (can be adjusted based on protocol) [9].	Can be prolonged compared to the fasted state [10].	Controlled by the peristaltic valve pumps and ileal efflux rate [1].
Typical Application	Predicting bioavailability of oral drugs in a fasting human; studying rapid absorption [10].	Assessing food effects on drugs/nutrients; simulating typical meal intake [9] [10].	Protocols are selectable for specific conditions (age, species, health status) [9].

Experimental Protocols for Fasted and Fed State Simulations

System Configuration and Pre-experiment Setup

• TIM System Selection: Choose the appropriate TIM configuration (e.g., TIM-1 for stomach and small intestine, tiny-TIM for higher throughput, TIM-agc for advanced gastric motility) based on the research objective [1].
• Parameter Programming: Load the respective fasted or fed state protocol into the TIM computer control software. This includes setting the specific curves for gastric emptying, pH in each compartment, and the timing and flow rates for all secretory fluids (saliva, gastric secretion, bile, pancreatin) as defined in Table 1.
• Preparation of Secretions: Prepare all artificial digestive fluids (saliva, gastric juice, bile, pancreatin) according to standardized, physiologically relevant compositions. For fed state simulations, ensure adequate volumes are prepared to accommodate the higher secretion rates [1].
• Test Meal/Formulation Preparation (Fed State):
  • For fed state experiments, a standardized meal is often used. A common high-fat meal model includes 11.7 g of protein, 13.2 g of carbohydrates, and 21.6 g of lipids, homogenized with water to a total volume of 300 mL [10].
  • The test compound (drug or nutrient) is mixed into the meal prior to introduction into the gastric compartment.
• Dosage Form Administration (Fasted State): In fasted state simulations for pharmaceutical testing, the solid oral dosage form (e.g., tablet, capsule) is introduced into the gastric compartment with a small volume of aqueous fluid (e.g., 50-100 mL water) to simulate administration with a fasting glass of water [10].

Execution and Sampling

• System Start-up: Initiate the TIM system according to manufacturer instructions, allowing the temperature (37°C) and initial conditions to stabilize.
• Meal/Dose Introduction: Introduce the test meal (fed) or the dosage form with water (fasted) into the gastric compartment.
• Sample Collection:
  • Dialysate/Filtrate: Collect samples from the dialysis (hydrophilic compounds) and filtration (lipophilic compounds) units connected to the jejunal and ileal compartments at predetermined time points. This fraction represents the bioaccessible compound [9] [1].
  • Chyme: Optionally, collect samples from different compartments (stomach, duodenum, jejunum, ileum) at various time points to study the progression of digestion and release.
• Analysis: Analyze collected samples using appropriate analytical techniques (e.g., HPLC, MS) to quantify the concentration of the compound of interest.

Case Study: Metformin Hydrochloride Tablets

A study investigating metformin HCl immediate-release (IR) and sustained-release (SR) tablets in a dynamic gastrointestinal system (DHSI-IV) demonstrates the critical impact of state simulation [10].

• Procedure: The protocols above were applied. Tablets were administered in both fasted and fed (high-fat meal) states.
• Key Findings:
  • IR Tablets: Food caused a significant delay in drug release and reduced the bioaccessible fraction to 76.2% of the fasted state value.
  • SR Tablets: The food effect was less pronounced, with a fed/fasted bioaccessibility ratio of 95.5%.
  • Predictive Power: Using in vitro bioaccessibility data in a convolution-based in silico model successfully predicted plasma concentration curves that mirrored clinical data in humans [10].

Table 2: Experimental Results for Metformin HCl Tablets in a Dynamic GI Model [10]

Dosage Form	State	Bioaccessible Fraction (Mean)	Fed/Fasted Ratio	Observed Release Profile
Immediate Release (IR)	Fasted	100% (Reference)	76.2%	Rapid release
Immediate Release (IR)	Fed	76.2%		Delayed and reduced release
Sustained Release (SR)	Fasted	100% (Reference)	95.5%	Controlled release over time
Sustained Release (SR)	Fed	95.5%		Slightly delayed but largely unimpaired release

The Scientist's Toolkit: Essential Research Reagents and Materials

Table 3: Key Research Reagent Solutions for TIM Experiments

Item	Function / Description	Physiological Role Simulated
Artificial Saliva	Contains electrolytes and α-amylase [1].	Initiates starch digestion in the oral phase; moistens the bolus.
Gastric Secretion	Contains electrolytes, pepsin, and often a fungal lipase [1].	Creates acidic environment for protein denaturation/digestion and initiates lipid digestion.
Duodenal Secretion	Contains electrolytes, bile salts, and pancreatin (a mix of pancreatic enzymes) [1].	Neutralizes gastric acid, emulsifies lipids (bile), and provides enzymes for carbohydrate, protein, and fat digestion.
Dialysis System	Membrane with a molecular weight cutoff (e.g., 10 kDa) connected to intestinal compartments [1].	Mimics passive absorption of water-soluble, low molecular weight digestion products across the intestinal mucosa.
Filtration System	50 nm filter that allows micelles to pass but retains fat droplets [1].	Mimics the absorption of lipophilic compounds incorporated into mixed micelles.
Standardized Meals	Well-defined compositions (e.g., high-fat) used in fed state protocols [10].	Provides a consistent and physiologically relevant food matrix to study food-effect interactions.

Workflow and System Logic

The following diagram illustrates the logical decision process and experimental workflow for establishing fasted and fed state simulations in the TIM system.

The internal structure and flow of the TIM-1 system, which is central to executing these protocols, is shown below.

Bioaccessibility, defined as the fraction of a compound that is released from its matrix and becomes available for intestinal absorption, serves as a critical predictor for the overall bioavailability and therapeutic efficacy of oral dosage forms [18]. The gastrointestinal tract (GIT) presents numerous dynamic barriers—including shifting pH environments, enzymatic activity, digestive secretions, and transit times—that can significantly alter drug release profiles [10] [25]. For drug development professionals, accurately assessing bioaccessibility is therefore paramount for forecasting in vivo performance, particularly for complex formulations like sustained-release products, nanomedicines, and drugs exhibiting poor solubility.

Within this context, TNO gastrointestinal models (TIM systems) have emerged as sophisticated tools that replicate human physiological conditions with high fidelity. These dynamic, multi-compartmental systems simulate key processes of the upper and lower GIT, incorporating realistic gastric emptying rates, gradual pH adjustments, and continuous secretion of digestive fluids [18] [10]. This application note details how TIM systems, alongside complementary in vitro approaches, can be leveraged to generate reliable, physiologically relevant bioaccessibility data for immediate-release and complex formulations, thereby strengthening in vitro-in vivo correlation (IVIVC) and streamlining the drug development pipeline.

Key Physiological and Formulation Considerations

Successful assessment of bioaccessibility requires a thorough understanding of both gastrointestinal physiology and formulation characteristics. The table below summarizes the critical parameters that must be considered and replicated in any advanced in vitro model.

Table 1: Key Factors Influencing Drug Bioaccessibility

Category	Specific Factor	Impact on Bioaccessibility
Physiological Variables	Gastric & Intestinal pH	Affects drug solubility and dissolution; influences stability of pH-sensitive APIs and enteric coatings [10] [25].
	Gastric Emptying & Intestinal Transit Time	Determines the residence time available for dissolution and release; a primary factor for sustained-release formulations [10] [25].
	Digestive Secretions (Enzymes, Bile)	Enzymes facilitate the breakdown of complex formulations; bile salts mediate the solubilization of lipophilic drugs [18] [25].
	Motility & Shear Forces	Impacts the disintegration of solid dosage forms and the mixing efficiency of drug particles with digestive fluids [10].
Formulation & Drug Properties	Dosage Form (IR vs. SR/ER)	Immediate-Release (IR) aims for rapid dissolution; Sustained/Extended-Release (SR/ER) controls release over time, making kinetics critical [10].
	Solubility & Permeability (BCS Class)	BCS Class II & IV drugs with low solubility are inherently at risk for poor bioaccessibility without formulation engineering [10] [26].
	Food Effects (Fasted vs. Fed State)	Food can delay gastric emptying, alter luminal pH, and interact with drugs, thereby increasing, decreasing, or delaying bioaccessibility [10].

Experimental Protocols for Bioaccessibility Assessment

This section provides a detailed methodology for assessing drug bioaccessibility using a dynamic gastrointestinal model, with a specific case study on metformin hydrochloride tablets.

Case Study: Metformin HCl IR and SR Tablets in a Dynamic System

Objective: To investigate the release profile and bioaccessibility of metformin hydrochloride from Immediate-Release (IR) and Sustained-Release (SR) tablets under simulated fasted and fed states using a dynamic human stomach-intestine (DHSI) system [10].

Materials:

• Drug Formulations: Metformin HCl IR tablets (250 mg) and SR tablets (500 mg).
• Simulated Gastrointestinal Fluids: Simulated Gastric Fluid (SGF), Simulated Intestinal Fluid (SIF). Prepare according to standard recipes (e.g., INFOGEST protocol), including enzymes like pepsin and pancreatin.
• Test Meals: For fed-state simulations, a high-fat meal (e.g., 30% fat content) or nutritional drink is used.
• Equipment: Dynamic Human Stomach-Intestine (DHSI-IV) system or equivalent TIM apparatus, HPLC system with UV detector for drug quantification, pH meter and probes.

Procedure:

• System Calibration & Setup:
  • Calibrate pH probes and temperature sensors. Set the DHSI system to physiological temperature (37°C ± 0.5).
  • Program the system to mimic the desired fasted or fed state profiles for gastric emptying, pH adjustment, and secretion rates based on human physiological data [10].

• Fasted State Simulation:

  • Begin with a fasted-state gastric volume (e.g., ~40 mL of SGF, pH ~1.6-2.0).
  • Administer the dosage form (IR or SR tablet) into the gastric compartment.
  • Initiate the dynamic program. In the fasted state, gastric pH may gradually increase from an initial low value, and gastric emptying follows a specific curve [10].

• Fed State Simulation:

  • Introduce the test meal into the gastric compartment.
  • Administer the dosage form with a small volume of water or mixed with the meal.
  • Initiate the dynamic program for the fed state, which typically features a higher initial gastric pH, slower gastric emptying kinetics, and different secretion patterns compared to the fasted state [10].

• Sample Collection:

  • Collect sequential samples from the gastric and intestinal (e.g., distal ileum) compartments at predetermined time points (e.g., 0, 15, 30, 60, 120, 180, 240 min).
  • Immediately treat samples to halt enzymatic activity (e.g., by placing on ice, dilution with methanol, or enzyme inhibition).

• Sample Analysis:

  • Centrifuge samples to obtain a clear supernatant, representing the bioaccessible fraction.
  • Analyze the drug concentration in the supernatant using a validated HPLC-UV method.
  • Calculate the cumulative bioaccessibility at each time point as a percentage of the total administered dose.

Data Analysis and IVIVC:

• Plot the cumulative bioaccessibility versus time to generate release profiles.
• Calculate pharmacokinetic (PK) parameters such as ( T{max} ) (time to maximum concentration) and ( C{max} ) (maximum concentration) from the bioaccessibility curve.
• A convolution-based approach can be used to convert the in vitro bioaccessibility data into predicted plasma concentration profiles, which can then be compared to clinical PK data to validate the model [10].

The workflow and data output from such a protocol are summarized in the diagram below.

Key Findings from the Metformin Case Study

The application of the above protocol yielded critical, quantitative insights into the performance of different formulations under varying physiological conditions.

Table 2: Bioaccessibility and Predicted PK Parameters of Metformin Tablets in the DHSI System [10]

Formulation	State	Bioaccessible Fraction (%)	Predicted C~max~ (ng/mL)	Predicted T~max~ (h)
Immediate-Release (IR)	Fasted	~100%	943.9 ± 25.7	2.0 ± 0.4
Immediate-Release (IR)	Fed	76.2% (of fasted state)	Not Reported	Delayed
Sustained-Release (SR)	Fasted	~100%	Not Reported	Not Reported
Sustained-Release (SR)	Fed	95.5% (of fasted state)	Not Reported	Delayed

The data clearly demonstrates a significant food effect on the IR formulation, where a high-fat meal reduced the bioaccessible fraction and delayed the release. In contrast, the SR formulation was notably less impaired by food, maintaining a high bioaccessible fraction. The predicted PK parameters for the IR tablet in the fasted state showed excellent agreement with clinical data from healthy subjects, validating the predictive power of the dynamic in vitro system [10].

The Scientist's Toolkit: Essential Reagents and Materials

To ensure physiological relevance and reproducibility in bioaccessibility studies, the use of standardized, high-quality reagents is imperative. The following table lists key materials required for setting up dynamic GI simulations.

Table 3: Key Research Reagent Solutions for Dynamic GI Models

Reagent / Material	Function in the Experiment	Key Considerations
Simulated Gastric & Intestinal Fluids	Provide the aqueous environment and ionic strength of the GIT lumen.	Composition must reflect physiological levels of salts, buffers, and surface-active components like bile salts [18] [10].
Digestive Enzymes (Pepsin, Pancreatin)	Catalyze the breakdown of dosage form matrices (e.g., polymer coatings, gelatin capsules) and food components.	Enzyme activity must be standardized and verified to ensure consistent and physiologically relevant digestion kinetics [18] [27].
Bile Salts	Emulsify hydrophobic compounds and facilitate the solubilization of lipophilic drugs, enhancing their bioaccessibility.	Concentration should be varied to reflect the difference between fasted and fed states [10] [25].
pH Adjustment Solutions (e.g., HCl, NaHCO₃)	Used to dynamically control the pH in different compartments, mimicking the gradual acidification in the stomach and neutralization in the intestine.	Automated titration systems are required for precise, real-time pH control as per physiological profiles [18].
Test Meals	Used in fed-state simulations to evaluate the impact of food on drug release and solubilization.	High-fat / high-calorie meals are often used for standardized food-effect studies, as per regulatory guidance [10].

Advanced Applications and Future Perspectives

The principles of bioaccessibility assessment are continually being adapted to meet the challenges posed by modern pharmaceutical innovations.

Beyond Small Molecules: The growing interest in oral biologics and nanoparticle-based drug delivery systems demands sophisticated models that can accurately capture their unique interactions with the GIT environment. TIM systems are particularly valuable here, as they can predict the stability of complex molecules and the fate of nano-engineered materials under digestive conditions [18] [26].

Miniaturization and Automation: Recent advances include the development of miniaturized semi-dynamic models, or "digestion-chips." These systems incorporate key dynamic features like gradual acidification and gastric emptying while using significantly smaller volumes of samples and reagents. This is especially beneficial for testing expensive or scarce new chemical entities (NCEs) and nanomaterials during early development stages [18].

Integration with Digital Tools: The future of bioaccessibility testing lies in the integration of dynamic physiological models with Artificial Intelligence (AI) and 3D printing (3DP). AI can optimize formulation design based on predictive models of bioaccessibility, while 3DP enables the creation of complex, personalized dosage forms with tailored release profiles, which can then be tested in systems like the TIM [28] [26].

In conclusion, a thorough, physiologically grounded assessment of drug bioaccessibility is a cornerstone of efficient drug development. By employing dynamic models like TIM systems and adhering to robust, detailed experimental protocols, researchers can generate highly predictive data, de-risk the development process, and ultimately deliver more effective and reliable therapeutics to patients.

The investigation of food effects—the influence of food intake on the oral absorption and bioavailability of drugs—is a critical area of research in drug development and personalized medicine. It is estimated that food affects the oral absorption of more than 40% of recently approved drugs [29]. These interactions can lead to complex fluctuations in drug absorption, including increased bioavailability (positive food effect) or decreased bioavailability (negative food effect), with significant implications for therapeutic efficacy and patient safety [29]. Understanding these mechanisms requires a sophisticated approach that can simulate the complex physiological changes induced by food ingestion in the human gastrointestinal (GI) tract.

This document presents Application Notes and Protocols for investigating food effect mechanisms using the TNO Intestinal Model (TIM), a dynamic in vitro system that replicates human GI conditions with high physiological relevance. The TIM platform, particularly the TIM-1 and tiny-TIMsgc systems, provides a controlled environment for studying how different meal types impact drug absorption kinetics, enabling researchers to predict food effects during early drug development stages [21]. These systems allow for the precise manipulation of parameters such as gastric pH, secretion rates, transit times, and mechanical forces, facilitating detailed investigation into the physiological mechanisms underlying food-drug interactions.

Physiological Mechanisms of Food Effects

Food ingestion triggers a cascade of physiological changes throughout the gastrointestinal tract that can significantly alter drug absorption patterns. Understanding these mechanisms is fundamental to designing appropriate experimental protocols for food effect studies.

Gastrointestinal Fluid Dynamics

The composition and characteristics of GI fluids undergo significant changes in the fed state. Gastric pH rises dramatically from fasting state values (pH ~1-2) to postprandial values (pH ~5-7) immediately after food intake, gradually returning to fasted state conditions over several hours [29]. This pH shift can profoundly affect the dissolution and stability of pH-sensitive drug compounds. Simultaneously, bile concentration increases in the small intestine, enhancing the solubility of poorly water-soluble drugs through micellar solubilization [29]. The volume of GI fluids also increases postprandially, potentially affecting drug concentration and absorption rates.

Motility and Transit Patterns

The gastrointestinal tract exhibits different motility patterns in fasted and fed states. During fasting, the migrating motor complex (MMC) creates cyclic periods of quiescence and intense motor activity that propel residual content through the GI tract [30]. Food ingestion suppresses the MMC and initiates a fed motor pattern characterized by continuous, low-amplitude contractions that mix and slowly propagate gastric content [30]. This shift directly impacts gastric emptying time, which is typically prolonged in the fed state, particularly for solid dosage forms and high-fat meals [29].

The TIM systems are dynamic, multi-compartmental models that simulate the physiological conditions of the human gastrointestinal tract. These systems provide a sophisticated alternative to human trials, which are "cost-prohibitive" and involve "ethical and operational barriers" [21], while offering significant advantages over simpler static models.

System Architecture and Design

The TIM-1 system comprises four sequential compartments representing the stomach, duodenum, jejunum, and ileum [21]. Each compartment features flexible walls housed within transparent rigid jackets. The stomach component in the newer tiny-TIMsgc model is designed with three parts: a vertical gastric body, a vertical proximal antrum, and a horizontal distal antrum, better mimicking the J-shape of the human stomach [21]. Temperature is maintained at 37°C through water circulation, and computer-controlled peristaltic movements simulate GI motility through modulated water pressure in the annular spaces between flexible walls and outer jackets [21].

Key Technological Features

The TIM systems incorporate several technologically advanced features that enable physiological relevance:

• Computer-controlled peristalsis: The systems simulate the propagating contractions of the gastric and intestinal walls by applying modulated water pressure to the flexible membranes, creating pressure forces validated with in vivo human data [21].
• Dynamic secretion system: Pumps deliver simulated GI secretions (gastric juice, bile, pancreatic fluids) at rates adjustable based on the test food or drug formulation [21].
• Real-time pH monitoring and adjustment: pH electrodes strategically placed throughout the system, particularly between the proximal and distal antral compartments, allow for continuous monitoring and automated adjustment of pH conditions [21].
• Semi-permeable membrane absorption: The intestinal compartments incorporate semi-permeable membranes that allow removal of digested products and water, simulating absorption processes [21].

Table 1: Technical Specifications of TIM System Components

Component	Physiological Correlate	Key Features	Control Parameters
Gastric Unit	Stomach	J-shaped design (tiny-TIMsgc), flexible walls, temperature control	pH, secretion rate, contraction force (2-18 mm Hg), emptying rate
Small Intestinal Unit	Duodenum, Jejunum, Ileum	Three sequential compartments, absorption interfaces	pH gradient, secretion rates, transit time, absorption capacity
Secretion System	Gastric, pancreatic, biliary secretions	Computer-controlled pumps, reservoir tanks	Flow rates, composition, timing of introduction
Monitoring System	In vivo sensing	pH electrodes, pressure sensors, temperature probes	Real-time data acquisition, feedback control

Experimental Protocols

This section provides detailed methodologies for investigating food effects using the TIM platform, with specific protocols tailored to different research objectives.

Standard Operating Procedure for Food Effect Studies

Protocol 1: Investigation of Meal Type Impact on Drug Bioavailability

Objective: To evaluate the effects of different meal types on the bioaccessibility and absorption kinetics of test compounds.

Materials and Reagents:

• TIM-1 or tiny-TIMsgc system
• Test drug compound (API or formulated product)
• Simulated gastric fluid (SGF)
• Simulated intestinal fluid (SIF)
• Fed state simulated gastric fluid (FeSSGF)
• Fed state simulated intestinal fluid (FeSSIF)
• High-fat meal model (e.g., 800-1000 calories, 50% fat)
• High-carbohydrate meal model
• High-protein meal model

Procedure:

• System Calibration: Calibrate all sensors (pH, pressure, temperature) according to manufacturer specifications. Validate pressure forces using standardized methods (target range: 2-18 mm Hg for gastric region) [21].
• Meal and Drug Preparation:
  • Prepare test meals according to standardized compositions (e.g., FDA high-fat meal recommendations).
  • Mix drug product with meal or administer separately according to study design.
  • For solid dosage forms, consider particle size and formulation characteristics.
• System Inoculation:
  • Introduce food-drug mixture into gastric compartment.
  • For fasted state comparisons, administer drug with 240 mL water after overnight fast simulation.
• Dynamic Digestion Phase:
  • Initiate gastric secretions: SGF for fasted state; FeSSGF for fed state.
  • Maintain temperature at 37°C throughout experiment.
  • Apply appropriate motility patterns: fed mode (continuous contractions) or fasted mode (MMC pattern).
  • Adjust gastric pH to simulate physiological profiles: fed state (initial pH ~5-6, gradual decrease); fasted state (pH ~1.5-2).
• Intestinal Transition Phase:
  • Transfer gastric chyme to intestinal compartments at controlled rates simulating physiological emptying.
  • Introduce bile and pancreatic secretions at fed or fasted state-appropriate concentrations.
  • Maintain intestinal pH gradient: duodenum (pH ~6), jejunum (pH ~6.5-7), ileum (pH ~7-7.5).
• Sampling and Analysis:
  • Collect samples from absorption membranes at predetermined time points (e.g., 0, 15, 30, 45, 60, 90, 120, 180, 240, 360 minutes).
  • Analyze samples for drug concentration using appropriate analytical methods (HPLC, LC-MS/MS).
  • Calculate pharmacokinetic parameters: C~max~, T~max~, AUC, and relative bioavailability.

Protocol for Mechanical Forces Validation

Objective: To validate the mechanical forces applied in the TIM system against in vivo data using standardized methods.

Materials: Agar gel beads of specific fracture strengths (0.1 N, 0.2 N, 0.3 N), pressure measurement system, calibration apparatus.

Procedure:

• Prepare agar gel beads with standardized diameters (e.g., 1.27 cm) and characterized fracture strengths [21].
• Introduce beads into gastric compartment and subject to standard digestion protocol.
• Measure breakdown kinetics and compare with in vivo human data using established validation metrics [21].
• Adjust mechanical parameters until in vitro breakdown profiles match in vivo data.

Meal-Type Impact Analysis

Different meal compositions elicit distinct physiological responses that can significantly alter drug absorption patterns. The TIM platform enables systematic investigation of these meal-type effects through controlled manipulation of test meals and monitoring of resulting changes in drug bioaccessibility.

Meal Composition and Physiological Response

The composition of food intake affects multiple GI parameters including secretion rates, motility patterns, and transit times. High-fat meals particularly stimulate bile secretion, which can dramatically enhance the solubility and absorption of lipophilic drugs [29]. The physical state of the meal (solid vs. liquid) also influences gastric emptying kinetics, with liquids typically emptying more rapidly than solids [30] [29].

Table 2: Meal-Type Effects on Gastrointestinal Physiology and Drug Absorption

Meal Type	GI Physiological Changes	Impact on Drug Absorption	Example Drugs Affected
High-Fat	Increased bile secretion, prolonged gastric emptying, enhanced solubilization	Typically increased absorption for BCS Class II drugs (positive food effect)	Danazol, Amiodarone [29]
High-Carbohydrate	Moderate bile stimulation, variable effects on gastric emptying	Variable effects; may decrease absorption for some compounds	Atenolol (when taken with apple juice) [29]
High-Protein	Increased gastric acid secretion, potential binding interactions	Complex effects; may increase or decrease absorption depending on drug properties	L-dopa (affected by protein binding) [29]
Fruit Juices	Altered transporter function, potential enzyme inhibition	Typically decreased absorption (negative food effect) for transporter substrates	Grapefruit juice interactions [29]

Case Studies in Meal-Type Effects

Case Study 1: High-Fat Meal and Lipophilic Drugs A study investigating the bioavailability of danazol, a poorly soluble lipophilic drug, demonstrated a five-fold increase in absorption when administered with a high-fat meal compared to the fasted state [29]. Using the TIM platform, researchers were able to correlate this positive food effect with enhanced solubilization in the intestinal phase due to increased bile secretion stimulated by the high-fat content. This mechanistic understanding helps explain why BCS Class II drugs (low solubility, high permeability) often demonstrate positive food effects.

Case Study 2: Fruit Juice Interactions Fruit juices such as grapefruit, orange, and apple juice can cause significant negative food effects for certain drugs. Research using the TIM system has elucidated the mechanisms behind these interactions, including inhibition of uptake transporters (e.g., OATP) and metabolic enzymes (e.g., CYP3A) in the intestinal epithelium [29]. For example, apple juice was shown to reduce the absorption of atenolol by approximately 40% through osmolality-mediated changes in luminal water volume and potential transporter interactions [29].

The Scientist's Toolkit: Research Reagent Solutions

Successful investigation of food effects requires carefully selected reagents and materials that simulate physiological conditions while providing reproducibility across experiments.

Table 3: Essential Research Reagents for Food Effect Studies

Reagent/Material	Composition/Characteristics	Function in Food Effect Studies	Application Notes
Simulated Gastric Fluid (SGF)	Pepsin, sodium chloride, HCl (pH 1.2-2.0)	Fasted state gastric environment simulation	Adjust pH to ~5-6 for fed state simulations
Fed State Simulated Gastric Fluid (FeSSGF)	Pepsin, buffers, pH ~5.0	Postprandial gastric conditions	Maintains higher initial pH to simulate food buffering
Simulated Intestinal Fluid (SIF)	Pancreatin, bile salts, buffers (pH 6.5-7.0)	Small intestinal environment	Critical for dissolution of lipophilic compounds
Fed State Simulated Intestinal Fluid (FeSSIF)	Higher bile salt concentration, pH 6.5	Postprandial intestinal conditions	Enhanced solubilization capacity for fed state
Standardized Meal Models	FDA high-fat meal: 800-1000 calories, 50% fat	Positive food effect studies	Provides consistent stimulus for bile release
Agar Gel Beads	Specific fracture strengths (0.1-0.3 N)	Mechanical force validation	Correlates in vitro breakdown with in vivo data [21]
Transporter Inhibitors	e.g., GF-120918 for P-gp inhibition	Mechanism elucidation studies	Identifies transporter-mediated food interactions

Data Analysis and Interpretation Framework

The quantitative data generated from TIM experiments requires systematic analysis to draw meaningful conclusions about food effect mechanisms and potential clinical implications.

Key Pharmacokinetic Parameters

Analysis of samples collected from TIM absorption membranes enables calculation of critical pharmacokinetic parameters that predict in vivo performance:

• Bioaccessibility Profile: The percentage of drug released from the formulation and available for absorption over time.
• Relative Bioavailability: Comparison of total drug absorption (AUC) between fed and fasted states.
• Absorption Kinetics: Rate of drug absorption (C~max~, T~max~) under different prandial conditions.
• Food Effect Classification: Categorization as positive, negative, or neutral food effect based on statistical differences in exposure parameters.

Correlation with Biopharmaceutical Classification

The data obtained from TIM food effect studies can be interpreted within the framework of the Biopharmaceutics Classification System (BCS) [29]:

• BCS Class I (High Solubility/High Permeability): Typically show minimal food effects, as confirmed by TIM studies.
• BCS Class II (Low Solubility/High Permeability): Often demonstrate positive food effects due to enhanced solubilization by bile salts.
• BCS Class III (High Solubility/Low Permeability): May show negative food effects due to delayed gastric emptying or transporter interactions.
• BCS Class IV (Low Solubility/Low Permeability): Exhibit variable and unpredictable food effects requiring case-by-case evaluation.

The TIM gastrointestinal model provides a sophisticated platform for investigating food effect mechanisms and meal-type impacts on drug absorption. By simulating the dynamic physiological changes that occur in the human GI tract under different prandial states, the TIM system enables researchers to:

• Elucidate Mechanisms: Identify specific physiological factors (solubilization, transit, metabolism) responsible for observed food effects.
• Predict Clinical Outcomes: Generate quantitative data that correlates with human pharmacokinetic studies, supporting regulatory submissions.
• Optimize Formulations: Develop drug products with minimized food effects or specific dosing recommendations.
• Support Personalized Medicine: Understand how different meal compositions affect drug absorption in diverse patient populations.

The protocols and application notes presented herein provide a framework for designing robust food effect studies using the TIM platform. When implementing these methods, researchers should consider the specific characteristics of their drug compound, select appropriate meal models based on the target patient population, and validate mechanical parameters to ensure physiological relevance. Through systematic application of these approaches, the TIM system serves as an invaluable tool in advancing our understanding of food-drug interactions and developing safer, more effective pharmaceutical products.

The prevalence of poorly water-soluble drug candidates presents a major challenge in pharmaceutical development, as low solubility often leads to inadequate bioavailability and therapeutic failure. For orally administered drugs, bioavailability is intrinsically linked to bioaccessibility—the fraction of a compound that is released from its dosage form and solubilized in the gastrointestinal fluids, making it available for intestinal absorption [31] [32]. Research indicates that over 80% of new chemical entities fall into Biopharmaceutics Classification System (BCS) Class II or IV, characterized by poor aqueous solubility [33] [34] [35].

Predictive in vitro tools are essential for evaluating the bioaccessibility of new formulations. Among these, the TNO Gastro-Intestinal Model (TIM) is a sophisticated dynamic system that closely mimics human digestive processes, including peristaltic movements, pH gradients, and the regulated addition of digestive enzymes and fluids [31] [36] [32]. This case study utilizes the TIM platform to investigate how advanced formulation strategies can overcome solubility barriers, thereby enhancing the bioaccessibility and potential bioavailability of poorly soluble drugs.

Formulation Strategies for Poorly Soluble Drugs

Formulation scientists categorize poorly water-soluble drugs based on the key property limiting their solubility. 'Brick-dust' molecules possess high melting points, where solubility is limited by strong crystal lattice energy. In contrast, 'grease-ball' molecules exhibit high lipophilicity (high log P), where solvation is the primary barrier [33]. This distinction guides the selection of appropriate formulation strategies, which can be broadly divided into three main categories.

Strategy	Key Technology Examples	Primary Mechanism of Action	Typical Drug Load	Suitability
Drug Nanoparticles	Wet media milling, High-pressure homogenization, Precipitation [33]	Increased surface area via particle size reduction; potential increase in saturation solubility [33]	High (up to 40% drug concentration reported) [33]	Broadly applicable; particularly useful for 'brick-dust' molecules [33]
Solid Dispersions	Amorphous Solid Dispersions (ASDs), Co-amorphous Systems (CAM) [33] [37]	Drug stabilization in high-energy amorphous state; improved dissolution rate and supersaturation [37] [35]	Moderate to High (CAM systems enable high drug loading) [37]	Ideal for 'brick-dust' molecules with high melting points [33] [37]
Lipid-Based Formulations	Self-emulsifying Drug Delivery Systems (SEDDS), Lipid Solutions [33] [35]	Drug dissolution in lipid carriers; enhanced solubilization and potential lymphatic transport [35]	Varies (can be limited by drug solubility in lipids) [35]	Best for lipophilic 'grease-ball' molecules [33] [35]

A promising advancement in solid dispersion technology is the development of drug-drug co-amorphous systems. These are single-phase amorphous systems containing two or more therapeutic drugs at a specific stoichiometric ratio. They not only enhance the solubility and physical stability of the individual drugs through intermolecular interactions but also provide a platform for combination therapy [37].

The TIM Gastrointestinal Model: A Tool for Predictive Bioaccessibility Assessment

The TIM systems are dynamic, multi-compartmental models that simulate the physiological conditions of the human gastrointestinal tract with high fidelity. These computer-controlled systems simulate key parameters, including temperature, gastric and intestinal pH, peristaltic mixing, secretion of digestive enzymes and bile, and absorption of water and digested products through semi-permeable membranes [31] [36] [6]. This dynamic environment provides a more predictive assessment of a drug's in vivo performance compared to simple static dissolution tests.

Two primary models used in pharmaceutical research are:

• TIM-1: Simulates the stomach and small intestine (duodenum, jejunum, and ileum) and is ideal for detailed, site-specific studies of drug release and bioaccessibility [31].
• tiny-TIM: A smaller, simplified version of TIM-1 that offers higher throughput and has been shown to provide excellent predictive quality for the bioaccessibility of immediate-release (IR) formulations under fasted-state conditions [31].

Experimental Protocol: Assessing Drug Bioaccessibility in the TIM-1 System

The following protocol is adapted from methodologies used in pharmaceutical bioaccessibility studies [31] [6].

Objective: To determine the small intestinal bioaccessibility of a poorly soluble drug from an enabled formulation under simulated fasted and fed state conditions.

Materials and Reagents:

• TIM-1 system equipped with stomach and small intestine compartments.
• Simulated gastric fluid (SGF) and simulated intestinal fluid (SIF).
• Gastric lipase, pepsin, pancreatin, and bile salts.
• Test formulation (e.g., drug nanocrystals, solid dispersion, lipid-based formulation).
• Placebo formulation (control).
• Dialysis membranes with appropriate molecular weight cut-off.
• HPLC system with validated analytical method for the drug compound.

Procedure:

• System Initialization: Start the TIM-1 system and set the temperature to 37°C. Pre-fill the stomach compartment with fasted-state or fed-state SGF, and the small intestinal compartments with corresponding SIF.
• Dosing: Introduce the test formulation, containing a known dose of the drug, into the gastric compartment. The formulation can be introduced as a powder, capsule, or suspension.
• Gastric Phase (0-2 h):
  • Maintain gastric pH according to the desired digestive state (e.g., pH ~1.5-2.0 fasted; pH ~3.0-5.0 fed).
  • Simulate gastric secretions (enzymes, HCl) and emptying using a pre-programmed curve. Gastric contents are gradually pumped into the duodenal compartment.
• Intestinal Phase (2-6 h):
  • Maintain intestinal pH via secretion of bicarbonate (pH ~6.5-7.5).
  • Continuously add pancreatin and bile salts to the duodenal compartment.
  • Simulate absorption of small molecules and water by collecting permeate from the jejunal and ileal dialysis membranes.
• Sampling:
  • Collect samples from the gastric, duodenal, jejunal, and ileal compartments at predetermined time points.
  • Continuously collect the dialysate from the jejunal and ileal compartments. This dialysate represents the bioaccessible fraction of the drug—the portion that has been solubilized and is available for absorption.
• Analysis:
  • Centrifuge all compartment samples to separate the solubilized drug from undissolved particles.
  • Analyze the supernatant and dialysate samples using HPLC to quantify the drug concentration.
  • Calculate the percentage bioaccessibility as: (Total drug mass in dialysate / Total drug dose administered) × 100%.

Case Study: Application of TIM Models in Formulation Development

Comparative Bioaccessibility of Enabled Formulations

Verwei et al. (2016) conducted a pivotal study evaluating the ability of TIM-1 and tiny-TIM to predict the human bioaccessibility of several poorly soluble drugs from different formulations [31]. The results demonstrate the critical role of formulation and the predictive power of TIM systems.

Drug Compound	Formulation Type	TIM Model Used	Dietary State	Key Bioaccessibility Finding
Ciprofloxacin	Immediate Release (IR) vs. Modified Release (MR)	TIM-1 & tiny-TIM	Fasted	Higher bioaccessibility from IR formulation in first 3-4 hours.
Nifedipine	Immediate Release (IR) vs. Modified Release (MR)	TIM-1 & tiny-TIM	Fasted	Higher bioaccessibility from IR formulation in first 3-4 hours.
Posaconazole	Not Specified	TIM-1 & tiny-TIM	Fasted & Fed	Presence of a food effect observed, consistent with human data.
Fenofibrate	Nano- vs. Micro-particle Formulation	TIM-1 & tiny-TIM	Not Specified	Higher bioaccessibility from nano-formulation.
Ciprofloxacin	IR Formulation	TIM-1 vs. tiny-TIM	Fasted	tiny-TIM showed higher initial bioaccessibility and a tmax similar to clinical data.

The data from TIM-1 and tiny-TIM accurately reflected clinical observations. For instance, the systems correctly predicted the absence of a food effect for ciprofloxacin and the presence of a significant food effect for posaconazole [31]. Furthermore, the ability of nanonization to enhance bioaccessibility was confirmed, with fenofibrate nanoparticles showing superior performance compared to microparticles [31]. This underscores the utility of TIM systems in rational formulation design and optimization.

The Impact of the Food Matrix

The composition of the food matrix can significantly influence drug bioaccessibility, a factor that TIM systems are uniquely equipped to investigate. A study on the bioaccessibility of active compounds from Alpinia officinarum root found that the dietary model significantly influenced the bioaccessibility of its active compounds, with the bioaccessibility of galangin ranging from 17.36% to 36.13% across different dietary models [32]. This highlights that the food matrix can either enhance or inhibit the release and solubilization of active compounds, an critical consideration for designing fed-state bioavailability studies.

The Scientist's Toolkit: Essential Reagents and Materials for TIM Experiments

Table 3: Key Research Reagent Solutions for TIM Bioaccessibility Studies

Reagent / Material	Function in the Experiment	Example Application / Note
Simulated Gastric & Intestinal Fluids	Provide the physiologically representative liquid environment for digestion.	Composition varies for fasted vs. fed state simulations (e.g., pH, buffer capacity).
Digestive Enzymes (Pepsin, Pancreatin, Lipase)	Catalyze the breakdown of dosage forms (e.g., polymer matrices, lipid filles) and food components.	Critical for simulating the chemical digestion of solid dispersions and lipid-based formulations.
Bile Salts	Act as biological surfactants, aiding in the solubilization of hydrophobic drugs.	Essential for predicting the performance of lipophilic ("grease-ball") drugs.
Dialysis Membranes	Simulate intestinal absorption by allowing passive diffusion of solubilized drug molecules.	The collected dialysate represents the bioaccessible fraction. Molecular weight cut-off must be selected appropriately.
Quality Control Analytics (HPLC/MS)	Precisely quantify the drug concentration in complex digestas and dialysate samples.	Enables pharmacokinetic modeling and calculation of key parameters like tmax and Cmax.

The challenge of poor solubility in modern drug development necessitates robust formulation strategies and predictive evaluation tools. This case study demonstrates that formulation approaches such as nanonization, solid dispersions (including novel co-amorphous systems), and lipid-based delivery can fundamentally alter the bioaccessibility profile of poorly soluble drugs. The TIM gastrointestinal models provide a critical bridge between in vitro formulation development and in vivo performance, offering a dynamic and physiologically realistic environment to assess bioaccessibility. By integrating these advanced formulation strategies with predictive models like TIM, scientists can de-risk development, optimize formulations for clinical success, and ultimately enhance the delivery of challenging drug candidates.

The TNO Gastrointestinal Model (TIM) systems, renowned for their predictive quality in pharmaceutical development, are increasingly pivotal in nutritional science for investigating the bioaccessibility of nutrients and plant bioactive compounds [9]. Bioaccessibility, defined as the fraction of a compound that is released from its food matrix and becomes available for intestinal absorption, is a critical determinant of the real nutritional value of foods and nutraceuticals [38]. For bioactive compounds from plant sources, clinical efficacy is not solely a function of their inherent biological activity but is fundamentally constrained by their liberation from the food matrix and stability throughout gastrointestinal transit [38] [23]. TIM systems, with their dynamic, computer-controlled simulation of human physiological conditions—including temperature, pH, gastric and pancreatic secretion rates, and peristaltic movements—provide a sophisticated in vitro platform to overcome the limitations of static digestion models [31] [9]. This application note details protocols and data generated using TIM models to advance the analysis of bioactive compounds beyond pharmaceutical applications, providing researchers with validated methodologies to predict the human bioaccessibility of nutrients and phytochemicals with high accuracy.

The TIM systems simulate the dynamic conditions of the human gastrointestinal tract. The TIM-1 model replicates the stomach and small intestine, while subsequent models can include the large intestine (TIM-2) [9]. These systems use computer-controlled peristaltic pumps and valves to simulate motility, dialysis or filtration membranes to model passive absorption, and incorporate physiological digestive secretions [9]. Key settings such as transit times, secretion rates, and pH gradients can be adapted to simulate specific human populations (e.g., infants vs. adults) or physiological states (e.g., fasted vs. fed) [31] [9].

Table 1: Comparison of TIM System Configurations for Bioactive Compound Analysis

Feature	TIM-1 System	tiny-TIM System
Primary Application	Detailed, site-specific release profiles; MR formulations; food effects [31]	Higher throughput; IR formulations [31]
Simulated Regions	Stomach, duodenum, jejunum, ileum [9]	Upper GI tract (stomach and small intestine) [31]
Key Advantage	Provides comprehensive data on the region-specific release and bioaccessibility of compounds [31]	Faster operation, uses smaller quantities of test material, predicts tₘₐₓ similar to clinical data for IR forms [31]
Example Findings	Similar protein and phospholipid bioaccessibility from different cheese matrices [39]	Higher bioaccessibility from immediate-release formulations under fasted state in first 30-90 min [31]

The predictive quality of TIM systems has been validated against human data for numerous compounds. A pivotal study demonstrated that both TIM-1 and tiny-TIM could accurately simulate the presence or absence of a food effect on the bioaccessibility of pharmaceutical compounds like posaconazole and ciprofloxacin, aligning with clinical observations [31]. This capability is directly transferable to food science, for instance, in assessing how a lipid-rich meal influences the bioaccessibility of lipophilic phytochemicals such as carotenoids.

Application Note: Bioaccessibility Analysis of Processed Broccoli

Experimental Protocol

The following protocol, adapted for TIM systems, is based on a recent investigation into the bioaccessibility of bioactive compounds in processed broccoli [23].

1. Sample Preparation:

• Obtain fresh broccoli (Brassica oleracea var. italica) and process it using common culinary methods (e.g., boiling or steaming for 5 minutes) [23].
• Divide the processed broccoli into portions and store them under refrigerated (4°C for 2 weeks) or frozen (-18°C for 2 months) conditions to simulate ready-to-eat product preservation [23].

2. TIM-1 System Setup (Fed State Simulation):

• Initial Conditions: Set the initial gastric pH to ~5.0. Pre-fill the stomach compartment with a standardized fed-state composition (e.g., Ensure Plus or similar nutritional drink).
• Digestive Secretions: Configure the system to secrete gastric acid (HCl), pepsin, pancreatin, and bile salts according to established physiological rates for the fed state.
• Transit Times: Program the gastric and intestinal transit times to reflect a typical meal digestion profile (e.g., gradual gastric emptying over 2-3 hours).
• Absorption Module: Utilize the integrated dialysis system or filtration units in the small intestinal compartments to collect the bioaccessible fraction, which represents compounds available for absorption [9].

3. Digestion Run:

• Introduce a standardized quantity (e.g., 10 g equivalent) of the test broccoli sample into the TIM-1 stomach compartment.
• Initiate the computer-controlled digestion process. Monitor parameters like pH and pressure throughout the run.
• Collect the bioaccessible fraction from the jejunal and ileal dialysates at regular time intervals to establish a bioaccessibility profile over time.

4. Sample Analysis:

• Centrifugation: Post-digestion, centrifuge the collected fractions to separate the aqueous phase (containing bioaccessible compounds) from undigested residue [23].
• Chemical Assays: Quantify total phenols (e.g., Folin-Ciocalteu method), flavonoids, and vitamin C in the aqueous phase using spectrophotometric or HPLC techniques [23].
• Antioxidant Capacity: Assess the retained antioxidant activity of the digested samples using assays such as ABTS or DPPH [23].

Results and Data Analysis

The bioaccessibility data obtained from the TIM-1 system provides a realistic estimate of the bioactive compounds surviving digestion.

Table 2: Bioaccessibility of Bioactive Compounds in Processed Broccoli After In Vitro Digestion (Adapted from [23])

Broccoli Sample	Total Phenols (mg GAE/100 g)	Total Flavonoids (mg QE/100 g)	Vitamin C (mg/100 g)	Antioxidant Capacity (ABTS, μmol TE/100 g)
Fresh Broccoli (Undigested)	610	295	120	1500
Fresh Broccoli (Digested)	215 (35.2%)	80 (27.1%)	12 (10.0%)	450 (30.0%)
Refrigerated Steamed (Digested)	180 (35.0%*)	65 (32.5%*)	15 (12.5%*)	400 (33.3%*)
Frozen Boiled (Digested)	110 (29.9%*)	40 (28.6%*)	8 (9.8%*)	250 (30.1%*)

Note: Values in parentheses represent the bioaccessibility percentage relative to the undigested counterpart of the same processing treatment. The undigested values for processed samples were lower than fresh (e.g., frozen boiled had 368 mg GAE/100 g total phenols before digestion) [23].

The data reveals significant losses of bioactive compounds during gastrointestinal digestion, with vitamin C being the most labile. Furthermore, processing methods like freezing and boiling can exacerbate these losses, highlighting the importance of evaluating the final nutritional quality of food after digestion, not just before consumption [23].

Figure 1: Experimental workflow for analyzing bioactive compounds using the TIM-1 system.

Advanced Protocol: Investigating Nano-Formulations for Improved Bioaccessibility

A key application of TIM systems is evaluating advanced delivery systems designed to enhance the poor bioavailability of many plant bioactive compounds [40].

1. Nano-Encapsulation Formulation:

• Prepare nano-encapsulated forms of the target bioactive (e.g., sulforaphane from broccoli or quercetin from onions) using methods such as emulsion-based delivery or phospholipid complexes [40].
• A control group of the non-encapsulated pure compound should be included.

2. TIM-1 System Setup (Fasted State Simulation):

• Initial Conditions: Set the gastric pH to a fasted state level (~1.5-2.0). The stomach compartment should be empty prior to dosing.
• Dosing: Introduce the nano-formulation and the control as a solution or suspension, typically with a volume of water.

3. Analysis and Comparison:

• Conduct the TIM-1 digestion run as described in Section 3.1.
• Quantify the bioaccessible fraction of the bioactive compound from both the nano-formulation and the control.
• Calculation: Calculate the relative bioaccessibility using the formula: (Bioaccessible amount from nano-formulation / Bioaccessible amount from control) * 100.

Studies have shown that such formulations can dramatically improve bioaccessibility. For instance, microencapsulation of broccoli sulforaphane increased its bioaccessibility from approximately 20% to nearly 70% during simulated digestion [23]. This protocol allows for the efficient screening of such delivery systems under physiologically relevant conditions before costly human trials.

The Scientist's Toolkit: Essential Research Reagents and Materials

The following table details key reagents and materials essential for conducting bioaccessibility studies with TIM systems.

Table 3: Key Research Reagent Solutions for TIM Experiments

Reagent / Material	Function in the Experiment	Example & Notes
Simulated Gastric Fluid	Mimics stomach secretions; initiates protein digestion and acid hydrolysis.	Contains NaCl, KCl, NaHCO₃, pepsin; pH adjusted to 1.5-2.0 (fasted) or ~5.0 (fed) [23].
Simulated Intestinal Fluid	Mimics pancreatic and biliary secretions; enables lipolysis and enzymatic digestion.	Contains NaCl, KCl, NaHCO₃, pancreatin, bovine bile salts; pH adjusted to 8.0 [23].
Dialysis Membranes / Filtration Units	Models passive absorption in the small intestine; separates the bioaccessible fraction.	Connected to jejunal and ileal compartments to collect dialysate [9].
Standardized Food	Creates physiologically accurate fed-state conditions for digestion studies.	Nutritional drinks like Ensure Plus; or defined meals like the FDA high-fat breakfast [31].
Nano-Encapsulation Matrices	Enhances solubility and protects labile bioactive compounds during GI transit.	Phospholipids (for liposomes), polysaccharides (e.g., chitosan), or proteins (e.g., whey protein) [40].

Figure 2: The journey of a bioactive compound through the TIM system, from the food matrix to the bioaccessible state.

Integrating the TIM gastrointestinal models into the research and development pipeline for nutraceuticals and functional foods provides an unparalleled, physiologically accurate tool for predicting the human bioaccessibility of nutrients and plant bioactive compounds. The detailed protocols and data presented herein demonstrate the systems' capability to reliably quantify the impact of food processing, storage, and formulation strategies on the release and stability of bioactive compounds. By employing TIM systems, researchers and product developers can make informed decisions early in the development process, optimize formulations for enhanced efficacy, and generate robust, human-relevant data that strengthens health claim substantiation, ultimately bridging the gap between food composition and tangible health benefits.

Navigating Challenges and Enhancing TIM Experiment Success

Within the framework of a broader thesis on the TNO gastro-Intestinal Model (TIM) for bioaccessibility research, this document addresses two recurrent and interconnected challenges: managing model complexity and mitigating fluid composition discrepancies. The TIM system is a dynamic, computer-controlled in vitro model that simulates the stomach, small intestine, and large intestine with high physiological accuracy [9]. Its predictive power for human bioaccessibility—the fraction of a compound available for intestinal absorption—is well-documented [9] [5]. However, the very complexity that underlies its success, coupled with potential inconsistencies in simulating gastrointestinal fluids, presents significant pitfalls that can compromise experimental outcomes. This document provides detailed application notes and protocols to help researchers navigate these challenges effectively.

The Pitfall of Model Complexity

The TIM system's sophistication is a double-edged sword. Its multi-compartmental, dynamic nature allows for the simulation of peristalsis, controlled transit times, passive absorption, and dynamic pH changes [9]. Nevertheless, this complexity requires meticulous setup and operation to ensure data reliability and predictive value.

Key Aspects of TIM Complexity

• Dynamic Parameter Management: The system must continuously regulate temperature, pH, secretion of digestive enzymes, and transit times [9]. Inappropriate settings, such as incorrect gastric emptying rates, can drastically alter bioaccessibility results.
• Physiological Validation: A model's predictive quality is contingent upon its validation against human data. Settings must be adapted to the specific condition being simulated, such as fasted versus fed states, age (e.g., pediatric populations), or health conditions [9] [5].
• Technical Operation: The use of flexible membranes and computer-controlled pumps to simulate motility requires precise calibration [9]. Malfunctions or miscalibrations can lead to unphysiological shear forces and mixing, affecting drug dissolution and food breakdown.

Quantitative Parameters Across TIM Systems

The table below summarizes critical variable parameters for different TIM configurations, highlighting the need for precise control.

Table 1: Key Variable Parameters in TIM Systems for Different Physiological States

Parameter	TIM-1 (Adult Fasted)	TIM-1 (Adult Fed)	TIMpediatric (Infant)	Reference
Initial Gastric pH	1.6 - 2.0	~5.0, decreasing to ~2.0	Higher than adult (age-dependent)	[5] [10]
Gastric Emptying Half-Time	~15-30 min	~2-4 hours	Shorter than adult; age-dependent	[5] [10]
Small Intestine pH (Duodenum to Ileum)	~6.0 - 7.5	~6.0 - 7.5	Similar gradient, potential differences in baseline	[9] [5]
Enzyme Secretion (e.g., Pepsin, Pancreatin)	Fasted state profile	Fed state profile (increased)	Lower activity; specific pediatric formulations	[41] [5]
Transit Time (Total Small Intestine)	~4-6 hours	~4-6 hours	Shorter than adult	[9] [5]

Protocol: System Setup and Calibration for a Standard Fed-State Adult Experiment

This protocol outlines the critical steps for initializing a TIM-1 system to simulate an adult fed state, a common source of complexity-related error.

Objective: To correctly configure and calibrate the TIM-1 system for a bioaccessibility study of an oral solid dosage form under fed-state conditions.

Materials:

• TIM-1 system (comprising stomach, duodenum, jejunum, and ileum compartments with flexible walls)
• Computer control unit and software
• pH electrodes and pumps for reagent secretion
• Water bath system for temperature control (37°C)
• Fed-state simulated gastric and intestinal fluids
• Digestive enzymes (e.g., pepsin, pancreatin)
• Calibration standards for pH meters

Methodology:

• System Initialization:
  • Fill the glass jackets surrounding the intestinal compartments with thermostated water to maintain a constant temperature of 37°C.
  • Flush all compartments with water and ensure dialysis or filtration units are correctly installed if used for absorption simulation [9].

• Parameter Programming:

  • In the control software, select the "Fed State" protocol.
  • Set the gastric pH profile: start at pH ~5.0 to simulate the buffering capacity of a meal, then program a gradual decrease to ~2.0 over 1-2 hours [10].
  • Program the gastric emptying kinetics. Use a biphasic curve (e.g., initial lag phase followed by linear emptying) with a half-time of approximately 2 hours.
  • Set the secretion rates for gastric acid, pepsin, pancreatin, and bile salts according to established fed-state profiles [9]. For example, pancreatin and bile salt secretion should be linked to gastric emptying into the duodenum.
  • Define the pH gradient along the small intestine, typically from ~6.0 in the duodenum to ~7.5 in the ileum, controlled by the secretion of bicarbonate [9].

• Calibration and Verification:

  • Calibrate all pH probes using standard buffers (e.g., pH 4.0, 7.0) prior to the experiment.
  • Perform a blank run without test material to verify the pH profiles, transit times, and temperature stability over the entire experimental duration.
  • Check the peristaltic mixing by observing the movement of the flexible membranes and the pressure readings from the water pumps.

The Pitfall of Fluid Composition Discrepancies

The composition of gastrointestinal fluids—including enzymes, bile salts, electrolytes, and pH—is a critical factor governing digestion, dissolution, and bioaccessibility. Inconsistent or unphysiological fluid composition is a major source of variability and predictive failure.

Critical Aspects of Fluid Composition

• Enzyme Sourcing and Activity: The purity, specific activity, and source (e.g., porcine vs. recombinant) of enzymes like pepsin and pancreatin can significantly impact proteolysis and lipolysis [41]. A systematic review of protein digestion models found that amylase, pepsin, and pancreatin were used in only 40% of studies, indicating a lack of harmonization [41].
• Bile Salt Composition and Concentration: The type (e.g., taurocholate vs. glycocholate) and concentration of bile salts directly affect the solubilization of lipophilic compounds and drugs.
• pH and Ionic Strength: The precise pH and ionic strength influence enzyme activity, compound solubility, and the charge state of molecules, thereby affecting their absorption potential.

Researcher's Toolkit: Essential Reagent Solutions

The following table details key reagents required for TIM experiments, their functions, and critical considerations to avoid discrepancies.

Table 2: Research Reagent Solutions for TIM Experiments

Reagent	Function & Physiological Role	Critical Considerations for Use
Pepsin	Gastric protease; initiates protein digestion in the stomach.	Use from porcine gastric mucosa; verify activity (e.g., Anson units/mg). Activity is highly pH-dependent (optimal ~2.0).
Pancreatin	Mixture of pancreatic enzymes (proteases, lipase, amylase); crucial for intestinal digestion.	Source (porcine) and batch-to-batch variability must be checked. Pre-fermentation of lipase is common in some protocols [9].
Bile Salts	Emulsify fats, form micelles for solubilizing lipophilic compounds.	Use a physiological mixture (e.g., tauro- and glyco-conjugates) at human-relevant concentrations (fed vs. fasted).
Electrolyte Solutions (NaCl, KCl, CaCl₂)	Maintain physiological ionic strength; Ca²⁺ is essential for lipase activity and fat precipitation.	Concentration affects osmolarity and enzyme kinetics. Calcium levels can influence the formation of insoluble soaps with fatty acids.
Mucin	Simulates the viscous mucus layer lining the GI tract.	Can bind to compounds and slow diffusion, affecting bioaccessibility. Often omitted but can be critical for some applications.

Protocol: Preparation of Simulated Gastrointestinal Fluids for a Fed-State Study

This protocol is adapted from harmonized methods like INFOGEST, which has been shown to effectively simulate human gastrointestinal protein processes [41].

Objective: To prepare standardized simulated gastric and intestinal fluids for a TIM experiment under fed-state conditions.

Materials:

• Potassium chloride (KCl), Sodium chloride (NaCl), Sodium bicarbonate (NaHCO₃), Calcium chloride dihydrate (CaCl₂·2H₂O)
• Porcine pepsin
• Porcine pancreatin
• Bovine bile salts
• Hydrochloric acid (HCl) and Sodium hydroxide (NaOH) for pH adjustment

Methodology:

• Simulated Gastric Fluid (SGF):
  • Prepare an electrolyte solution: Dissolve KCl, NaCl, and other salts in reverse osmosis water according to the INFOGEST protocol.
  • Adjust the pH to 3.0 using HCl.
  • Add porcine pepsin to a final activity of 2000 U/mL in the final mixture. The enzyme must be added just before use to prevent activity loss.
  • The final SGF should be used immediately in the TIM gastric compartment.

• Simulated Intestinal Fluid (SIF):
  • Prepare an electrolyte solution with a higher concentration of bicarbonate to buffer incoming gastric chyme.
  • Adjust the pH to 7.0 using NaOH.
  • Add porcine pancreatin and a physiological mixture of bovine bile salts. The final concentrations should reflect fed-state levels (e.g., bile salts at ~10 mM; pancreatin activity must be standardized, e.g., 100 U/mL of trypsin activity).
  • Calcium chloride is typically added separately during the experiment via a secretion pump to avoid precipitation in the stock SIF.

Integrated Experimental Workflow and Visualization

A robust experimental workflow integrates the management of both model complexity and fluid composition. The diagram below outlines the logical sequence and key decision points for a successful TIM experiment.

Diagram 1: TIM Experiment Workflow

Case Study: Impact of Pitfalls on Drug Bioaccessibility

A study on metformin hydrochloride tablets in a dynamic gastrointestinal system (DHSI-IV) exemplifies the real-world impact of these factors. The research demonstrated that a high-fat meal significantly delayed gastric emptying and reduced the bioaccessible fraction of metformin from immediate-release (IR) tablets to 76.2% of the fasted state value [10]. This food effect was accurately captured because the model correctly simulated the complex fed-state physiology (addressing model complexity) and used appropriate fluid compositions. In contrast, a simpler, static dissolution apparatus would likely fail to predict this effect, leading to an overestimation of bioaccessibility in the fed state.

The power of TIM systems for predicting human bioaccessibility is contingent upon a rigorous approach to managing model complexity and fluid composition. By adhering to validated protocols, meticulously calibrating systems, and using physiologically relevant fluids, researchers can avoid these common pitfalls. The integrated workflow and detailed protocols provided here serve as a guide to enhance the reliability and predictive quality of TIM experiments, thereby strengthening their value in drug and nutrient development and reducing the need for animal and human trials.

The TNO gastrointestinal model (TIM) is a cornerstone of advanced in vitro research for predicting the bioperformance of nutrients and oral drugs. A critical analysis of its operational parameters reveals two significant limitations concerning its physiological accuracy: the handling of lipid phase separation and the elevation of bile salt concentrations in the fasted state. This application note details these limitations, provides quantitative comparisons to human physiological data, and offers validated experimental protocols to enhance the bio predictive power of TIM-based bioaccessibility research.

Critical Limitations in TIM Systems

Absence of Lipid Phase Separation in Fed State Conditions

A primary physiological discrepancy in TIM systems, particularly tiny-TIM, is the behavior of lipids in the fed state. Human intestinal fluids (HIF) undergo phase separation, forming a distinct lipid layer. In contrast, tiny-TIM intestinal fluids (TIF) remain monophasic. This is attributed to the system's use of bile salt concentrations that are 5.3 times higher than those found in human HIF. These elevated levels effectively solubilize all lipids into the micellar phase, preventing the natural separation process [42].

This absence of a lipid phase can lead to an overestimation of the solubilizing capacity for poorly water-soluble compounds. The monophasic environment creates an artificially high and constant solubilization potential, which does not fully replicate the dynamic and heterogeneous solubilization process occurring in the human intestine [42].

Non-Physiological Bile Salt Concentrations in the Fasted State

The composition of fasted-state fluids in TIM systems also shows significant deviations from human physiology. A meta-analysis of human data shows that bile salt concentrations are highly variable along the gastrointestinal tract, with the highest variability observed in the fasted-state duodenum [43]. When compared to this human data, fasted-state TIF exhibits elevated bile salt levels, with a TIF/HIF ratio of 1.8. Concurrently, lipid concentrations in fasted-state TIF are lower than in HIF (TIF/HIF ratio of 0.27) [42]. This imbalance disrupts the natural composition and solubilization kinetics of intestinal fluids, which can compromise the bio predictiveness of dissolution and absorption studies for certain compounds.

Table 1: Quantitative Comparison of Tiny-TIM Intestinal Fluids (TIF) vs. Human Intestinal Fluids (HIF)

Parameter	Human Intestinal Fluids (HIF)	Tiny-TIM Intestinal Fluids (TIF)	Ratio (TIF/HIF)	Physiological Impact
Fasted State Bile Salts	Variable (High inter-subject variability) [43]	Elevated	1.8 [42]	Over-prediction of solubilizing capacity
Fasted State Lipids	Variable	Lower	0.27 [42]	Altered solubilization environment
Fed State Bile Salts	Physiological baseline	Elevated	5.3 [42]	Prevents lipid phase separation
Fed State Lipid Phase	Biphasic (separated lipid layer) [42]	Monophasic (no separation) [42]	N/A	Creates non-physical solubilization matrix

Experimental Protocols for System Characterization and Adjustment

Protocol for Determining Solubilizing Capacity

This protocol is designed to directly compare the solubilizing capacity of TIF versus HIF or other biorelevant media for poorly soluble drugs, as demonstrated in prior studies [42].

1. Objective: To quantify the potential overestimation of drug solubility in TIM systems due to altered bile salt and lipid levels. 2. Materials:

• TIM intestinal fluid (TIF) from fasted or fed state experiments
• Biorelevant media (e.g., FaSSIF/FeSSIF) or, if available, characterized HIF
• Poorly water-soluble model drug compound
• Centrifuge filters (e.g., 100 kDa molecular weight cut-off)
• HPLC system with appropriate detector

3. Procedure: 1. Sample Preparation: Generate TIF by running a standard TIM experiment, collecting fluid from the relevant intestinal compartment. 2. Equilibration: Add an excess of the model drug compound to aliquots of TIF and reference media (HIF or biorelevant media). 3. Incubation: Incubate the mixtures at 37°C with continuous agitation for 4-6 hours to reach equilibrium. 4. Separation: Centrifuge the samples using centrifuge filters to separate the micellar phase containing solubilized drug from undissolved drug and any lipid phase. 5. Analysis: Quantify the concentration of the drug in the filtrate using HPLC. 6. Calculation: Calculate the apparent solubility in each medium. Compare the solubility in TIF versus reference media to determine the overestimation factor.

Protocol for Monitoring Bile Salt-Mediated Protein Interactions

The elevated bile salt levels in TIM can alter protein digestion and conformation. This protocol assesses these interactions using spectroscopy [44].

1. Objective: To characterize the structural changes induced in dietary proteins (e.g., β-Lactoglobulin) by TIM-level bile salt concentrations. 2. Materials:

• Protein of interest (e.g., β-Lactoglobulin)
• Sodium taurocholate (NaTC) or a physiologically relevant bile salt mixture
• Spectrofluorometer
• CD (Circular Dichroism) spectrometer
• Buffers simulating gastric (pH 3.0) and intestinal (pH 6.2) conditions

3. Procedure: 1. Sample Preparation: Prepare protein solutions in gastric and intestinal buffers. Titrate with increasing concentrations of bile salts (0-20 mM). 2. Fluorescence Spectroscopy: Monitor the intrinsic fluorescence of tryptophan residues (excitation ~280 nm, emission ~300-400 nm). A red shift and change in intensity indicate protein unfolding [44]. 3. Circular Dichroism: Record far-UV CD spectra (190-250 nm). Analyze changes in the spectra to quantify alterations in the protein's secondary structure (e.g., loss of alpha-helicity) [44]. 4. Data Analysis: Plot spectral changes against bile salt concentration to determine the critical aggregation concentration (CAC) and the extent of structural modification at TIM-relevant bile salt levels.

The Scientist's Toolkit: Research Reagent Solutions

Table 2: Essential Reagents for Investigating TIM Limitations

Reagent/Material	Function & Application	Key Considerations
Sodium Taurocholate (NaTC)	A primary conjugated bile salt used to simulate intestinal surfactant activity [44].	Critical for creating micellar phases; concentration must be carefully selected to avoid non-physiological solubilization [42].
β-Lactoglobulin (BLG)	Model dietary protein used to study bile salt-protein interactions and proteolysis kinetics under simulated GI conditions [44].	Its resistance to gastric digestion makes it ideal for studying intestinal-phase interactions [44].
Centrifuge Filters	Used to separate the micellar phase from undissolved drug and lipid phases during solubility studies [42].	Molecular weight cut-off (e.g., 100 kDa) should be sufficient to retain micelles while allowing dissolved drug to pass.
Simulated Intestinal Fluids	Biorelevant media like FaSSIF/FeSSIF serve as a more physiologically accurate benchmark for comparing TIF solubilization capacity [42].	Provide a standardized reference point against which to validate TIM fluid compositions.

Visualization of Workflow and Interactions

TIM Limitations and Analysis Workflow

Bile Salt-Protein Interaction Mechanism

Predictive in vitro tools are essential in pharmaceutical research for evaluating the bioaccessibility of Active Pharmaceutical Ingredients (APIs) before conducting human trials. The TNO Gastro-Intestinal Model (TIM) systems are advanced, dynamic models that simulate the physiological conditions of the human gastrointestinal tract. These systems are particularly valuable for investigating populations where clinical trials are challenging, such as pediatric and elderly patients, due to ethical and practical constraints [31] [45]. By accurately replicating parameters like temperature, pH, secretion of digestive fluids, and peristaltic movements, TIM systems can provide critical data on how age-related physiological differences affect drug release and absorption [46] [47]. This application note details optimized protocols for using TIM-1 and tiny-TIM systems to simulate the gastrointestinal environments of these specific populations, supporting formulation development and dose selection.

The TIM-1 and tiny-TIM systems are computer-controlled dynamic models designed to simulate the stomach and small intestine. The key difference lies in their scale and application focus. TIM-1 is a larger, more comprehensive system that allows for detailed, site-specific sampling throughout the gastrointestinal tract, making it ideal for studying modified-release (MR) formulations and complex food effects [31]. In contrast, tiny-TIM is a smaller-scale model that offers higher throughput and is particularly well-suited for the rapid screening of immediate-release (IR) formulations [31] [47].

Table 1: Comparison of TIM-1 and tiny-TIM Systems for Population Studies

Feature	TIM-1 System	tiny-TIM System
Primary Application	Modified-release (MR) formulations, site-specific release, food effects [31]	Immediate-release (IR) formulations, higher-throughput screening [31] [47]
Predictive Quality	Provides detailed information on site-specific API release, relevant for MR formulations [31]	Better prediction of early exposure (tmax) for IR formulations; profiles align well with clinical data [31] [47]
Throughput	Lower throughput due to complexity and detailed sampling [31]	Higher throughput, enabling more rapid evaluation of formulations [31]
Model Fidelity	Computer-controlled dynamic simulation of gastric & intestinal conditions [47]	Computer-controlled dynamic simulation of gastric & intestinal conditions [47]

Protocol 1: Simulating Pediatric Gastrointestinal Conditions

Background and Rationale

Conducting clinical trials in pediatric populations presents significant practical and ethical challenges [45]. Physiological factors such as gastric pH, intestinal transit times, and enzyme activity levels change dramatically with growth and maturation, meaning that drug bioavailability in children cannot be extrapolated directly from adult data [45] [48]. TIM systems offer a valuable in vitro tool to bridge this data gap. Model-informed drug development (MIDD) approaches, including the use of Physiologically Based Pharmacokinetic (PBPK) models, are highly recommended by regulatory bodies like the European Medicines Agency (EMA) for quantifying the effects of growth and maturation on dose-exposure-response relationships [48].

Experimental Protocol for Pediatric Simulation

Objective: To evaluate the bioaccessibility of an oral drug formulation under conditions simulating the gastrointestinal environment of a specific pediatric age group (e.g., neonate, infant, child).

Materials:

• TIM-1 or tiny-TIM system
• Test formulation (oral solid or liquid dosage form)
• Pediatric-specific simulated gastric and intestinal fluids
• Dialysis membranes (e.g., cellulose) for bioaccessibility assessment [46]

Methodology:

• System Parameterization: Set the TIM system parameters based on the target pediatric population [48]:
  • Gastric pH: Adjust fasted-state gastric pH to age-appropriate levels (e.g., higher pH in neonates).
  • Gastric Emptying: Program emptying kinetics to reflect slower rates in infants.
  • Intestinal pH and Secretions: Adjust the pH gradient and secretion rates of enzymes (e.g., pancreatin) and bile salts according to known ontogeny patterns.
  • Transit Times: Set small intestinal transit times to be potentially longer than in adults.

• Digestion Experiment:

  • Introduce the test formulation into the gastric compartment with the appropriate pediatric fasted or fed-state simulated fluid.
  • Initiate the dynamic digestion process, following the predefined temperature, secretion, and emptying profiles.
  • Collect samples from the intestinal compartment (e.g., from the jejunal and ileal dialysate in TIM-1) at predetermined time points.

• Bioaccessibility Analysis:

  • Analyze the collected samples using a validated analytical method (e.g., HPLC, LC-MS/MS) to quantify the dissolved API concentration [46].
  • Calculate the percentage of bioaccessible API over time, generating a bioaccessibility profile.

Data Interpretation and Integration with PBPK

The bioaccessibility profiles obtained from the TIM system serve as a critical input for PBPK models for children. These models integrate system-specific parameters (e.g., organ weights, blood flows, tissue compositions) with drug-specific properties to predict pharmacokinetics [45] [48]. When developing a pediatric PBPK model, it is essential to account for body size through allometric scaling (typically using fixed exponents of 0.75 for clearance and 1.0 for volume of distribution) and for organ maturity using maturation functions (e.g., sigmoidal Emax models for renal or metabolic clearance) [48]. The TIM-derived bioaccessibility data can replace or validate the absorption model within the PBPK framework, leading to more reliable predictions of dose-exposure relationships and more rational pediatric dose selection [45].

Protocol 2: Simulating Elderly Gastrointestinal Conditions

Background and Rationale

The aging process leads to physiological changes that can alter the pharmacokinetics of drugs, including their absorption in the GI tract [49] [50]. Age-related changes such as reduced gastric acid secretion, altered gastrointestinal motility, and decreased splanchnic blood flow can potentially impact drug bioaccessibility and bioavailability [49] [50]. Furthermore, polypharmacy is common in the elderly, increasing the risk of drug-drug interactions that may further complicate absorption [49] [51]. Using TIM systems to simulate the aged GI tract allows researchers to study these effects in a controlled setting, providing data to optimize formulations and dosing regimens for older adults.

Experimental Protocol for Geriatric Simulation

Objective: To assess the effect of age-related GI changes on the bioaccessibility of an oral drug formulation, including potential food and polypharmacy effects.

Materials:

• TIM-1 system (recommended for its detailed sampling capabilities in complex scenarios)
• Test formulation
• Elderly-specific simulated gastrointestinal fluids (e.g., with adjusted pH)
• Co-administered medications (for interaction studies) [49]

Methodology:

• System Parameterization: Configure the TIM-1 system to reflect common age-related physiological changes [49] [50]:
  • Gastric pH: Increase fasted-state gastric pH to simulate achlorhydria or hypochlorhydria.
  • Gastric Emptying: Slightly delay gastric emptying kinetics to model slowed motility.
  • Intestinal Transit: Consider minor adjustments to intestinal transit times.
  • Transporters: While complex to model, the potential for altered function of efflux transporters like P-glycoprotein should be considered.

• Digestion Experiment with Food and Drug Interactions:

  • For food-effect studies, introduce a standardized "elderly" meal composition alongside the drug.
  • For polypharmacy studies, introduce a second drug (a known P-gp substrate or inhibitor) into the system simultaneously with the test formulation.
  • Run the dynamic digestion process and collect intestinal samples as before.

• Bioaccessibility and Data Analysis:

  • Quantify the API and, if applicable, the interacting drug.
  • Compare bioaccessibility profiles (e.g., AUC, Cmax, Tmax) under fasted, fed, and polypharmacy conditions to those from adult simulations.

Integration with PBPK for Elderly Populations

PBPK modeling is a well-established tool for predicting drug exposure in special populations, including the elderly [49] [51]. To develop a PBPK model for older adults, age-related changes in organ function, body composition (increased fat, decreased water), and potential reductions in hepatic and renal clearance must be incorporated [51] [50]. The TIM-generated data on absorption in the aged gut can be used to verify and refine the absorption component of an elderly PBPK model. This combined approach is particularly powerful for informing dosage adjustments for drugs with a narrow therapeutic index in a population often excluded from early-stage clinical trials [51].

Table 2: Key Age-Related Physiological Changes and Their Simulation in TIM Systems

Physiological Parameter	Pediatric Consideration	Elderly Consideration	TIM Simulation Approach
Gastric pH	Higher in neonates, approaches adult values by ~3 years [48]	Tendency towards higher pH (achlorhydria) [50]	Adjust initial gastric fluid composition and pH-stat set points.
Gastric Emptying	Slower in infants, becomes faster than adults in children [48]	Can be delayed [50]	Modify the gastric emptying kinetics profile in the software.
Intestinal Transit	May be longer in infants [48]	Can be slightly prolonged [50]	Adjust the peristaltic pump settings for intestinal passage.
Enzyme/ Bile Levels	Maturation of pancreatic function and bile salt pool [48]	Generally stable, but can be affected by co-morbidities [50]	Use age-appropriate concentrations in secretion fluids.

Case Study Data and Analysis

Validation studies have demonstrated the predictive power of TIM systems for bioaccessibility. The following table summarizes quantitative data from a study that evaluated different APIs and formulations in TIM-1 and tiny-TIM, which can serve as a benchmark for protocol development [31] [47].

Table 3: Summary of Bioaccessibility Findings from TIM System Validation Studies

API	Formulation	Condition	TIM System	Key Bioaccessibility Finding	Correlation with Human Data
Fenofibrate	Micro-particle	Fasted	TIM-1	Lower bioaccessibility [31]	Predictive of relative formulation performance [31]
Fenofibrate	Nano-particle	Fasted	TIM-1	3.30% (vs micro-particle) [31]	Predictive of relative formulation performance [31]
Fenofibrate	Micro-particle	Fasted	tiny-TIM	Lower bioaccessibility [31]	Predictive of relative formulation performance [31]
Fenofibrate	Nano-particle	Fasted	tiny-TIM	6.40% (vs micro-particle) [31]	Predictive of relative formulation performance [31]
Posaconazole	IR	Fasted	Both	Low bioaccessibility [31] [47]	Matches observed low human bioavailability [47]
Posaconazole	IR	Fed	TIM-1	~13.8x increase vs fasted [47]	Confirms positive food effect seen in humans [31]
Ciprofloxacin	IR & MR	Fasted/Fed	Both	High (>90%) and consistent [31] [47]	Aligns with complete absorption in humans [31]

The Scientist's Toolkit: Research Reagent Solutions

Table 4: Essential Materials for TIM Experiments in Population-Specific Research

Item	Function/Description	Application Note
TIM-1 or tiny-TIM Apparatus	Core system with computer-controlled pumps, vessels, and sensors to simulate GI physiology.	TIM-1 is ideal for detailed, site-specific studies (e.g., MR formulations). tiny-TIM offers higher throughput for IR screening [31].
Simulated Gastric Fluid (SGF)	Aqueous solution with electrolytes and often pepsin, pH-adjusted to target population.	For elderly simulations, pH may be set higher (~pH 5-6) to mimic hypochlorhydria. For infants, a higher pH is also used [49] [48].
Simulated Intestinal Fluid (SIF)	Aqueous solution with electrolytes, pancreatin, and bile salts.	Concentrations of bile salts and enzymes can be adjusted to reflect the ontogeny in children or changes in the elderly [48].
Dialysis Membranes	Semi-permeable membranes (e.g., cellulose) separating intestinal content from absorbable fraction.	Used to model the passage of dissolved compounds across the intestinal barrier for bioaccessibility measurement [46].
Standardized Meals	Defined compositions of carbohydrates, proteins, and fats for fed-state experiments.	Crucial for studying food effects, which can be pronounced in the elderly or for specific pediatric nutritional regimens [31] [49].

The TIM gastrointestinal models, when configured with population-specific physiological parameters, provide a powerful and predictive in vitro platform for optimizing drug formulations and dosing for pediatric and elderly patients. The protocols outlined herein enable researchers to generate high-quality bioaccessibility data that, when integrated with PBPK modeling, can significantly de-risk the drug development process for these vulnerable populations. This approach aligns with regulatory encouragement for using model-informed drug development to overcome ethical and practical challenges, ultimately leading to safer and more effective medicines for all age groups [45] [48].

Integrating TIM with Mucosal Transit Assays and Caco-2 Cell Models

The accurate prediction of human oral bioavailability is a critical challenge in drug and nutraceutical development. The TNO Gastrointestinal Model (TIM) is a sophisticated, dynamic in vitro system that simulates the human gastrointestinal tract, providing high-quality data on the bioaccessibility of compounds—the fraction that is released from the food or dosage form and becomes available for intestinal absorption [9]. However, to fully predict bioavailability, data on intestinal absorption is required. This application note details robust methodologies for integrating the TIM system with mucosal transit assays and advanced Caco-2 cell models to create a powerful, predictive platform for assessing compound absorption. This integrated approach bridges the gap between bioaccessibility and bioavailability, offering a more complete in vitro tool for research and development [9] [52].

Key Research Reagent Solutions

The following table details essential reagents and materials required for the integrated experiments described in this protocol.

Table 1: Essential Research Reagents and Materials

Reagent/Material	Function/Application	Key Details
Porcine Mucin (Type III)	Protects Caco-2 monolayers from bile salt damage in biorelevant media [52].	Used at 15 mg/mL or 50 mg/mL to form a protective physical barrier [52].
Vasointestinal Peptide (VIP)	Stimulates robust mucus production in Caco-2 cells [53] [54].	Added to the basolateral compartment (e.g., 100 nM) during Air-Liquid Interface (ALI) culture.
TIM-Derived Luminal Fluids	Biorelevant media for permeability assays [52].	Captures complex prandial state-dependent solubilization; superior to simple FaSSIF/FeSSIF.
Porcine Bile Extract	Provides physiological bile salts for micelle formation in TIM and permeability assays [52].	Critical for lipid digestion and solubilization of lipophilic compounds.
Simulated Digestive Fluids	Enable physiologically relevant digestion in the TIM system [9].	Include gastric juice, pancreatic juice, and bile, secreted with gradual pH changes.

Integrated Workflow: From TIM to Cellular Absorption

The following diagram illustrates the complete experimental workflow, from dynamic gastrointestinal simulation in TIM to cellular absorption assessment.

Quantitative Data from Integrated Models

The integration of TIM with absorption models generates crucial quantitative data for predicting human absorption.

Table 2: Bioaccessibility and Permeability Data from Integrated Models

Compound / Model	Key Parameter	Result	Significance
EPA as Phospholipid (PL) in TIM [55]	Bioaccessibility	75-80%	Significantly higher than MAG (30%) or TAG (38%) forms.
EPA as Triacylglycerol (TAG) in TIM [55]	Bioaccessibility	38%	Demonstrates profound formulation impact on bioaccessibility.
Reference Drugs in Mucin-Caco-2 [52]	Correlation (fa vs Papp)	Sigmoidal Relationship	Permeability data predicts human fraction absorbed (fa).
Caco-2 Assay [56]	Predictive Correlation (fa vs log Papp)	R² = 0.76	Validates Caco-2 as predictive tool for human intestinal absorption.

Detailed Experimental Protocols

Protocol 1: Generating Bioaccessible Fractions using the TIM System

This protocol outlines the procedure for simulating gastrointestinal passage using the TIM-1 system, which models the stomach and small intestine [9].

Key Steps:

• System Setup: Initialize the TIM-1 system with compartments for the stomach and small intestine (duodenum, jejunum, ileum). Set physiological parameters: temperature (37°C), pH gradients (stomach: fasted ~2.5, fed ~5.0; small intestine: ~6.5-7.5), and secretion rates for gastric juice, pancreatic juice, and bile [9].
• Meal Introduction: Introduce the test meal (e.g., drug formulation or food) into the gastric compartment. The system can be programmed for fed-state or fasted-state conditions [9] [55].
• Dynamic Digestion: Run the computer-controlled digestion process. This includes peristaltic mixing, gradual acidification and enzyme secretion in the stomach, and controlled gastric emptying into the small intestine compartment [9].
• Sample Collection: Collect the bioaccessible fraction from the small intestine compartment using an integrated dialysis or filtration unit (e.g., with a 0.05 μm cut-off membrane). This filtrate contains the compounds solubilized in the mixed micelles of the digestive fluids, representing the fraction ready for absorption [9] [55]. The collected TIM luminal fluid can be used directly or stabilized for subsequent cellular assays [52].

Protocol 2: Establishing a Functional Mucus Layer with the ALI-VIP Caco-2 Model

This protocol describes how to culture Caco-2 cells to form an intestinal mucosal model with a native mucus layer, enhancing physiological relevance [53] [54].

Key Steps:

• Cell Seeding: Seed Caco-2 cells at a density of 400,000 cells/mL onto the apical side of Transwell inserts. Culture them for 7-8 days in standard medium, changing the basolateral medium every 2-3 days until a confluent monolayer is formed [53] [52].
• Air-Liquid Interface (ALI) Induction & VIP Stimulation: Remove the apical medium to expose the cell surface to air. Simultaneously, add vasointestinal peptide (VIP, e.g., 100 nM) to the basolateral compartment. Continue culture for a defined period (e.g., 4-6 days) to induce mucus production and differentiation [53] [54].
• Mucus Layer Validation: Verify the formation of a functional mucus layer. This can be done via:
  • Immunofluorescence (IF): Stain for the secreted mucin MUC2 and use the lectin Jacalin (JAC) to visualize the glycosylated mucus layer on top of the epithelium [53].
  • qRT-PCR: Confirm the upregulation of mucin genes (e.g., MUC2, MUC13, MUC17) [53].

The diagram below illustrates the key differences between this advanced model and traditional cultures.

Protocol 3: Permeability Assessment with Mucin-Protected Caco-2 Assay

This protocol is optimized for evaluating drug permeability using biorelevant media from TIM, which can be cytotoxic to standard Caco-2 cells [52].

Key Steps:

• Cell Culture: Grow Caco-2 cells on Transwell inserts for 21 days or a shortened 7-8 day protocol to form a confluent, differentiated monolayer. Monitor integrity by measuring Transepithelial Electrical Resistance (TEER) [52] [56].
• Mucin Protection: Prior to the permeability assay, apply a solution of porcine mucin (Type III, 15-50 mg/mL in HBSS) to the apical side of the cell monolayer and incubate (e.g., 30-60 minutes). This forms a protective, artificial mucus layer [52].
• Permeability Experiment: Replace the apical medium with the TIM-generated luminal fluid containing the test compound. For the basolateral compartment, use a physiologically buffered solution like HBSS, optionally supplemented with 0.5% Bovine Serum Albumin (BSA) to improve sink conditions and recovery for lipophilic compounds [52] [56].
• Sampling and Analysis: Incubate the system at 37°C with shaking. Collect samples from the basolateral compartment at regular intervals over 2-3 hours. Analyze the samples using HPLC-MS/MS to determine the apparent permeability coefficient (Papp) of the test compound [52] [56].

Application Case Study: Venetoclax (BCS Class IV)

A case study on venetoclax, a poorly soluble and permeable drug (BCS Class IV), demonstrates the power of this integrated approach [52].

• TIM Bioaccessibility: Luminal fluids generated by the tiny-TIM system showed a higher solubilization capacity for venetoclax compared to standard bioremedia like FaSSIF/FeSSIF [52].
• Mucin-Protected Permeability: The TIM-derived luminal fluid was then used as the donor solution in a mucin-protected Caco-2 assay. The mucin layer was essential to maintain cell monolayer integrity during the experiment [52].
• Integrated Readout: The combination provided a more mechanistic and predictive readout of venetoclax's permeation, effectively capturing the complex interplay between solubilization in the GI lumen and subsequent absorption across the intestinal epithelium under different prandial states [52].

The integration of the dynamic TIM system, which provides highly predictive bioaccessibility data, with advanced Caco-2 models featuring functional mucus layers creates a powerful, physiologically relevant in vitro platform. This combined approach successfully bridges the critical gap between the release of a compound in the gastrointestinal tract and its potential for intestinal absorption. By providing detailed, validated protocols and showcasing a practical application, this application note empowers researchers to implement this strategy. This integrated methodology significantly enhances the predictive power of in vitro studies, de-risks drug and nutraceutical development, and can substantially reduce the need for animal testing in human bioavailability prediction [9] [52].

Leveraging TIM Data for Robust In Silico Modeling and Prediction

The TNO Gastro-Intestinal Model (TIM) represents a category of dynamic, computer-controlled in vitro systems that simulate the human gastrointestinal tract with high physiological relevance [1]. These multi-compartmental models simulate dynamic conditions including gastric and intestinal transit, secretion of digestive fluids, changing pH values, and absorption of water and digested compounds [1]. The primary quantitative output from TIM experiments is bioaccessibility—the fraction of a compound that is released from the food or drug matrix and becomes available for absorption through the intestinal wall [1]. When combined with in silico modeling approaches, TIM-generated data provides a powerful tool for predicting human bioavailability, potentially replacing animal studies and increasing the success rates of subsequent human trials [4].

TIM Systems and Technical Specifications

The TIM platform comprises several configurations, each designed to address specific research questions while maintaining physiological relevance.

Table 1: TIM System Configurations and Their Applications

System	Compartments	Key Features	Primary Applications
TIM-1 [1]	Stomach, Duodenum, Jejunum, Ileum	Four sequential compartments; dialysis/filtration units for metabolite removal; programmable secretion flows	Comprehensive studies of gastric and small intestinal digestion; bioaccessibility of nutrients and drugs
tiny-TIM [1] [14]	Stomach, Single Small Intestinal	Simplified design; higher throughput; maintains physiological gastric conditions	Rapid screening studies; formulation development; effect of food and acid-reducing agents
TIM-agc [1]	Advanced Gastric Compartment only	Mimics shape and motility of human stomach; simulated antral waves and pyloric sphincter opening	Detailed study of gastric emptying; solid dosage form behavior; food disintegration

Quantitative Parameters and Physiological Simulation

TIM systems simulate human gastrointestinal conditions through precisely controlled parameters derived from in vivo data. These parameters can be adapted to various physiological states including age (infant, adult, elderly), prandial state (fed or fasted), and specific health conditions [4] [1]. The systems utilize computer simulations to dictate:

• Gastric and intestinal transit times based on established mathematical models [1]
• pH profiles that dynamically change in response to secretion rates and meal composition [1]
• Secretion rates of digestive fluids (saliva, gastric juice, bile, pancreatin) [1]
• Temperature control maintained at 37°C through water-jacketed compartments [1]
• Removal of digestion products through dialysis membranes (water-soluble compounds) and filtration systems (lipophilic compounds) [1]

Experimental Protocols for TIM Bioaccessibility Studies

Standardized Protocol for Bioaccessibility Assessment

The following protocol outlines a standardized approach for determining bioaccessibility using the TIM-1 system, adaptable for pharmaceutical or nutritional studies.

Table 2: Standardized TIM Protocol for Bioaccessibility Assessment

Protocol Step	Specifications	Parameters & Measurements
Meal Preparation	Solid foods: masticate using food processor; Mix with artificial saliva containing electrolytes and α-amylase [1]	Particle size distribution; Enzyme activity validation
Gastric Phase	Initial pH: based on meal composition; Gradual acidification with HCl to ~2.0 over 1-2 hours; Gastric secretion: electrolytes, pepsin, lipase [1]	pH monitoring; Samples for compound degradation analysis
Intestinal Phase	Duodenal secretion: electrolytes, bile, pancreatin; pH controlled with NaHCO₃ (Jejunum: ~6.5, Ileum: ~7.2) [1]	Dialysate collection from jejunal/ileal compartments; Filtered fraction collection for lipophilic compounds
Sample Collection	Continuous collection from dialysis/filtration systems; Time points: 0, 30, 60, 90, 120, 180, 240 min [4]	Quantitative analysis of target compound; Metabolic profiling if applicable
Data Analysis	Bioaccessibility = (Amount in dialysate/filtered fraction ÷ Total amount ingested) × 100% [1]	Kinetic modeling; Statistical analysis of replicates

Specialized Protocol for Drug Formulation Studies

For pharmaceutical applications, the tiny-TIM system with advanced gastric compartment (TIM-agc) provides mechanistic insights into drug product performance. The following protocol is adapted from itraconazole formulation studies [14]:

• System Preparation: Calibrate pH electrodes and pumps. Pre-warm all compartments to 37°C. Prepare simulated digestive fluids according to fasted or fed state conditions.
• Dosing: Introduce drug formulation through gastric compartment entry port. For solid dosage forms, use intact tablets/capsules to evaluate disintegration.
• Sampling Strategy: Collect samples from multiple ports—gastric, duodenal, and jejunal—to create intraluminal concentration profiles.
• Analysis: Quantify dissolved drug concentration using UHPLC/PDA. Compare with solubility measurements in biorelevant media.
• Data Interpretation: Calculate bioaccessible fraction over time. Correlate intraluminal profiles with formulation characteristics.

Integration of TIM Data with In Silico Modeling

Data Flow and Model Integration

The integration of TIM-generated data with computational models follows a structured workflow to maximize predictive accuracy for human bioavailability.

Research Reagents and Essential Materials

Successful implementation of TIM studies requires carefully standardized reagents and materials that simulate physiological conditions.

Table 3: Essential Research Reagents for TIM Experiments

Reagent/ Material	Composition	Physiological Function	Application Notes
Artificial Saliva [1]	Electrolytes, α-amylase	Initial digestion of carbohydrates; Bolus formation	Prepare fresh before experiment; Adjust electrolyte concentration for age/species
Gastric Secretion [1]	Electrolytes, pepsin, fungal lipase (as gastric lipase alternative)	Protein digestion; Lipid hydrolysis; Acidification	pH-dependent enzyme activity; Fed vs. fasted state concentration differences
Duodenal Secretion [1]	Electrolytes, bile salts, pancreatin	Neutralization of gastric chyme; Lipid emulsification; Comprehensive nutrient digestion	Bile concentration affects lipophilic compound bioaccessibility
Dialysis Membranes [1]	~10 kDa molecular weight cutoff	Removal of water-soluble digestion products	Mimics passive absorption in small intestine
Filtration System [1]	50 nm filters	Removal of lipophilic compounds incorporated in micelles	Critical for assessing fat-soluble vitamin and drug bioaccessibility

Case Study: Protocol Application and Validation

Itraconazole Formulation Analysis

A published study demonstrated the application of tiny-TIM to investigate different itraconazole formulations under physiologically relevant conditions [14]. The study specifically examined:

• Formulations Compared: Amorphous solid dispersion (ASD)-based formulation versus cyclodextrin-based oral solution
• Experimental Conditions: Fasted state, fed state (high-fat meal), and modified gastric pH (simulating acid-reducing agents)
• Sampling Methodology: Multiple sampling ports allowed measurement of intraluminal concentration profiles in addition to bioaccessible fraction
• Key Finding: The model successfully predicted the positive food effect and impact of gastric pH modification for the ASD formulation, correlating well with in vivo data
• Limitation Identification: The negative food effect observed in vivo for the solution formulation was not predicted, highlighting that formulation effects on permeation must be considered for complete prediction

This case study validates TIM as a mechanistic tool for formulation development while acknowledging the importance of complementary assays for certain formulation technologies.

Advanced Applications and Future Directions

Multi-Scale Modeling Framework

The integration of TIM data with advanced in silico approaches enables comprehensive predictive modeling of compound behavior in humans.

Emerging Applications

Beyond conventional bioavailability prediction, the TIM-in silico combination shows promise for:

• Pediatric and Geriatric Formulations: Adaptation of TIM parameters to simulate age-specific gastrointestinal conditions [4]
• Food-Drug Interactions: Systematic investigation of meal effects on drug absorption [14]
• Nutraceutical Bioavailability: Optimization of delivery systems for bioactive compounds [4]
• Personalized Medicine: Development of patient-specific models based on individual gastrointestinal parameters

The integration of TIM gastrointestinal models with in silico approaches represents a robust methodology for predicting human bioavailability of both pharmaceutical compounds and nutrients. The physiological relevance of TIM systems, combined with their reproducibility and adaptability to various conditions, provides high-quality input data for computational models. Following the standardized protocols outlined in this document enables researchers to generate reliable bioaccessibility data that, when combined with appropriate absorption and pharmacokinetic modeling, can significantly reduce the need for animal studies and increase the success rate of subsequent human trials. As both TIM technology and computational models continue to evolve, this integrated approach promises to become increasingly accurate and essential in drug development and nutritional research.

Validation and Comparative Analysis: TIM's Predictive Power for Human Outcomes

In the development of new oral drugs, particularly those with poor solubility, predicting human bioavailability represents a significant challenge. The translational gap between pre-clinical models and human outcomes often leads to costly late-stage failures in drug development [57]. The TNO Gastro-Intestinal Model (TIM) is a multi-compartmental dynamic model designed to bridge this gap by realistically simulating the dynamic conditions within the human gastrointestinal lumen [1]. This application note details how TIM systems, through the measurement of bioaccessibility (the fraction of a compound available for absorption), are validated against human clinical pharmacokinetic data, providing a highly predictive tool for drug development.

The core strength of TIM technology lies in its ability to simulate crucial physiological parameters in a controlled and reproducible manner. These parameters include gastric and small intestinal transit times, flow rates and composition of digestive fluids, pH changes, and removal of water and metabolites [1]. By combining TIM bioaccessibility data with additional in silico kinetic modeling, researchers can achieve a highly predictive estimation of a drug's in vivo performance, thereby reducing the reliance on animal studies and increasing the success rate of subsequent human trials [9].

TIM System Configurations and Their Applications

The TIM platform comprises several systems, each optimized for specific research needs. The configurations most relevant for bioaccessibility and pharmacokinetic correlation studies are the TIM-1 and tiny-TIM systems.

Table 1: TIM Systems for Upper GI Tract Bioaccessibility Studies

System	Compartments	Key Features	Best Use Cases
TIM-1 [1] [57]	Stomach, Duodenum, Jejunum, Ileum	Four compartments; gradual transit; site-specific sampling; dialysis/filtration for metabolite removal.	Modified-release (MR) formulations; site-specific release; detailed food-effect studies.
tiny-TIM [1] [57]	Stomach, Single Small Intestine	Simplified, higher throughput; single intestinal compartment with plug-flow transit.	Immediate-release (IR) formulations; rapid formulation screening; pediatric and elderly models.
TIM-agc [1]	Advanced Stomach	Mimics shape and motility of the stomach; realistic antral waves and pyloric sphincter opening.	Studying the impact of gastric motility on drug formulations.

Validation Evidence: Correlating TIM Bioaccessibility with Human Pharmacokinetics

The predictive quality of the TIM systems is demonstrated by strong correlations between in vitro bioaccessibility data and in vivo human plasma concentration data for a variety of drug compounds.

Systematic Evaluation and Case Studies

A comprehensive evaluation of TIM-1 versus clinical data demonstrated a correct in vivo rank order prediction of 84% for AUC (Area Under the Curve) and 79% for Cmax (maximum plasma concentration) across nine different Active Pharmaceutical Ingredients (APIs) in 19 immediate-release formulations [57]. The following case studies further illustrate this predictive power.

Table 2: Summary of TIM Validation Studies Against Human Pharmacokinetic Data

Drug Compound / Formulation	TIM System	Key Bioaccessibility Finding	Correlation with Human Pharmacokinetics
Ciprofloxacin (IR) [57]	TIM-1 vs. tiny-TIM	Earlier tmax, bioacc in tiny-TIM (15-45 min) vs. TIM-1 (30-60 min).	Earlier tmax in tiny-TIM matched human clinical tmax more closely.
Posaconazole [57]	TIM-1 & tiny-TIM	Significant positive food effect on bioaccessibility.	Correctly predicted the positive food effect observed in human clinical data.
Fenofibrate [57]	TIM-1 & tiny-TIM	Higher bioaccessibility from nano- vs. micro-particle formulation.	Correctly predicted the superior relative bioavailability of the nano-formulation in humans.
Zongertinib (SDD vs. Conventional) [58]	tiny-TIM	SDD maintained bioaccessibility under high gastric pH; conventional formulation showed reduced bioaccessibility.	Predicted the ~35% higher AUC in humans for SDD and its resilience to acid-reducing agents.

Integrated Workflow for Predictive Biopharmaceutics

The journey from a TIM experiment to a predicted human pharmacokinetic profile involves a structured, multi-stage workflow that integrates in vitro and in silico tools.

Detailed Experimental Protocol: Bioaccessibility Assessment of Oral Formulations

This protocol outlines the methodology for assessing the small intestinal bioaccessibility of oral drug formulations using the TIM-1 system under simulated fed or fasted state conditions, as validated in pharmaceutical research [57].

Pre-experiment Setup

• TIM-1 System Preparation: Ensure all four compartments (stomach, duodenum, jejunum, ileum) are connected and the flexible walls are intact. Circulate water at 37°C outside the walls.
• Solution Preparation:
  • Artificial Saliva: Prepare with electrolytes and α-amylase.
  • Gastric Secretion: Contains electrolytes, pepsin, and fungal lipase.
  • Duodenal Secretion: Contains electrolytes, bile (e.g., porcine bile extract), and pancreatin.
  • Sodium Bicarbonate Solution (1M): For pH control in the intestinal compartments.
  • Hydrochloric Acid (1M): For gastric pH control.
• Dialysis/Filtration System: Install hollow-fiber dialysis membranes (10 kDa cutoff) connected to the jejunal and ileal compartments to remove digested products. For lipophilic compounds, a 50 nm filter unit is used to separate micelles [1].
• Test Formulation: Weigh the exact dose of the drug product. Tablets or capsules can be placed in a pharmaceutical stainless steel sinker to simulate swallowing [57].

Experimental Procedure

• Initialization.

  • Start the computer-controlled system and load the pre-defined digestive protocol (e.g., "Adult Human, Fasted State").
  • Flush all secretion lines with their respective solutions.

• Oral & Gastric Phase (0-2 hours).

  • Time = 0 min: Introduce the masticated drug product (mixed with artificial saliva) into the gastric compartment.
  • Initiate gastric secretion according to the pre-set flow rate.
  • The gastric pH is continuously measured and titrated with HCl to follow a pre-determined curve (e.g., starting at ~pH 5.0, dropping to ~pH 1.5-2.0 over 1-2 hours) [1] [57].
  • Gastric emptying is dictated by the Elashoff equation, with chyme transferred to the duodenum via peristaltic valve pumps.

• Intestinal Phase (0-6 hours).

  • As gastric chyme enters the duodenum, the duodenal secretion (bile and pancreatin) is started.
  • The pH in the duodenum, jejunum, and ileum is maintained at pre-set values (e.g., ~6.5, 7.0, and 7.5, respectively) using automatic titration with NaHCO₃.
  • Dialysis fluid is circulated on the other side of the hollow-fiber membranes. The amount of drug collected in the dialysate over time represents the bioaccessible fraction.
  • Alternatively, the filtrate from the 50 nm filter is collected for lipophilic drugs.

• Sampling and Monitoring.

  • Collect dialysate/filtrate samples from the jejunal and ileal systems at regular intervals (e.g., every 15-30 minutes).
  • Collect samples from each TIM compartment at key time points for additional analysis if needed.
  • Monitor and record pH, temperature, and pressure (for mixing) continuously throughout the experiment.

Data Analysis

• Analyze Drug Concentration: Use HPLC-MS/MS or other validated analytical methods to quantify the drug concentration in the dialysate/filtrate samples.
• Calculate Bioaccessibility: For each time interval, calculate the cumulative percentage of the administered dose that has become bioaccessible. Cumulative Bioaccessibility (%) = (Total amount of drug in dialysate up to time t / Administered dose) * 100
• Generate Profiles: Plot the bioaccessibility-time profile. Key parameters like maximum bioaccessibility (BA_max) and the time to achieve it (t_{max, bioacc}) can be derived and compared to human pharmacokinetic parameters (C_max and t_max).

The Scientist's Toolkit: Essential Research Reagents and Materials

Table 3: Key Reagents and Materials for TIM Experiments

Item	Function in the Protocol	Example/Note
Pancreatin	Provides key digestive enzymes (proteases, lipases, amylases) for intestinal digestion.	Porcine origin is commonly used. Activity should be standardized [1].
Bile Salts / Bile Extract	Emulsifies fats, facilitates formation of mixed micelles for lipophilic compound solubility.	Porcine bile extract is often used to simulate human bile [57].
Pepsin	Primary protease in the stomach, breaks down proteins.	Added to the gastric secretion solution [1].
Electrolyte Solutions	Creates physiologically relevant ionic strength and osmolarity in all digestive fluids.	Includes salts of K+, Na+, Ca2+, Cl-, etc. [1].
Dialysis Membranes	Mimics passive absorption; removes small molecules and water-soluble digestion products.	Typically 10 kDa molecular weight cutoff [1].
Lipophilic Filters	Removes lipophilic digestion products incorporated in micelles.	50 nm pore size [1].
pH Control Reagents	HCl and NaHCO3 solutions to dynamically control pH in different compartments.	Critical for simulating the precise pH gradient of the GI tract [1] [57].

The validation of the TIM gastrointestinal model against human clinical pharmacokinetic data establishes it as a powerful and reliable tool in biopharmaceutical research. Its ability to accurately predict the in vivo performance of various drug formulations, including the effects of food and release characteristics, underlines its value in de-risking formulation development and optimizing clinical trial design. By providing highly predictive human-relevant data, the TIM platform represents a cornerstone of the growing emphasis on the 3Rs (Replacement, Reduction, and Refinement of animal testing) and model-informed drug development.

Within biopharmaceutical research, predicting the in vivo performance of oral drug formulations is essential for efficient drug development. The TNO Gastro-Intestinal Model (TIM) systems are among the most advanced dynamic in vitro models that simulate the human gut environment. This application note provides a detailed comparison of two systems—TIM-1 and tiny-TIM—framed within a thesis on bioaccessibility research. It offers structured data, experimental protocols, and practical guidance to help scientists select the appropriate model based on their specific formulation needs, with the aim of improving the predictive quality of pre-clinical assessments.

System Characterization and Comparative Analysis

The TIM-1 and tiny-TIM systems are dynamic, computer-controlled models designed to simulate the physiological conditions of the human stomach and small intestine. Their core differences lie in their design complexity and operational throughput, which directly influence their application for different formulation types.

TIM-1 is a multi-compartmental system that realistically simulates the stomach, duodenum, jejunum, and ileum as separate compartments. It features gradual gastric and intestinal emptying, continuous removal of water and digested products via dialysis and filtration, and allows for site-specific sampling along the entire small intestine [1]. This makes it particularly suited for detailed, mechanistic studies.

Tiny-TIM is a simplified version designed for higher throughput. It incorporates a single small intestinal compartment instead of three, and does not include an ileal efflux. All fluids entering the small intestine are removed through a filtration or dialysis membrane, simulating intestinal transit as a traveling "plug" of chyme [1] [57]. This design is more efficient for rapid, comparative studies.

Table 1: Key Structural and Functional Differences between TIM-1 and tiny-TIM

Feature	TIM-1	Tiny-TIM
Compartments	Stomach, Duodenum, Jejunum, Ileum [1]	Stomach, Single Small Intestinal Compartment [1]
Small Intestinal Transit	Gradual "flow-through" simulation [1]	"Plug flow" simulation [1]
Ileal Efflux	Present, allows for absorption estimation [1]	Absent [1]
Throughput	Lower, more complex setup [57]	Higher, simplified operation [57]
Primary Strength	Detailed, site-specific release profiles [57]	Predictive for IR formulations, high throughput [57]

The following diagram illustrates the fundamental structural differences in the configuration of the two systems:

System Configurations of TIM-1 and tiny-TIM

Performance Data for Formulation Assessment

Validation studies directly comparing the bioaccessibility output of TIM-1 and tiny-TIM against human pharmacokinetic data have demonstrated their predictive value, while also highlighting performance nuances.

A pivotal study investigated four poorly soluble APIs in various formulations (immediate-release (IR) and modified-release (MR)) under fasted and fed conditions [57]. For ciprofloxacin IR, both systems showed similar bioaccessibility profiles, but tiny-TIM reached the maximum bioaccessible amount (BAmax) earlier (15-45 minutes) compared to TIM-1 (30-60 minutes). This earlier peak in tiny-TIM more closely matched the time to maximum concentration (tmax) observed in human clinical data [57]. For MR formulations of nifedipine, both models correctly predicted a delayed and sustained release profile compared to the IR formulation, with TIM-1 providing more detailed site-specific information [57].

Both systems accurately predicted the presence or absence of a food effect. For posaconazole, a positive food effect was correctly predicted by both models, while for ciprofloxacin, the absence of a food effect was also correctly predicted [57]. Furthermore, both TIM systems successfully discerned the performance of a fenofibrate nano-formulation versus a micro-particle formulation, showing higher bioaccessibility from the nano-formulation [57].

Table 2: Comparative Bioaccessibility Performance for Different Formulation Types

Formulation Type	Example API	TIM-1 Performance	Tiny-TIM Performance	Correlation with Human Data
Immediate Release (IR)	Ciprofloxacin	Accurate BAmax, slightly delayed tmax [57]	Accurate BAmax, earlier tmax matching clinical data [57]	High; tiny-TIM predicted tmax more accurately [57]
Modified Release (MR)	Nifedipine	Detailed site-specific release profile [57]	Correct sustained release profile [57]	High; TIM-1 provides more mechanistic insight [57]
Formulations with Food Effect	Posaconazole	Correctly predicted positive food effect [57]	Correctly predicted positive food effect [57]	High for both systems [57]
Nano- vs. Micro- Formulations	Fenofibrate	Higher bioaccessibility from nano-formulation [57]	Higher bioaccessibility from nano-formulation [57]	High for both systems [57]
ASD-Based Formulations	Itraconazole	N/A	Successfully predicted food effect and impact of gastric pH modification [14]	High for complex physiological conditions [14]

Detailed Experimental Protocols

To ensure reproducible and physiologically relevant results, adherence to validated experimental protocols is critical. The following section outlines a standard procedure for a fed-state bioavailability study.

Protocol: Fed State Bioaccessibility Assessment of a Poorly Soluble Drug

Objective: To determine the small intestinal bioaccessibility of a poorly soluble drug from an IR formulation under fed conditions using the TIM systems.

1. Pre-Experiment Setup:

• System Preparation: Calibrate pH electrodes and pumps. Pre-warm all compartments to 37°C. Load digestive secretions into respective reservoirs [1].
• Meal Preparation: For the fed state, a high-fat meal or standard nutritional drink is recommended. The meal should be mixed with artificial saliva (containing electrolytes and α-amylase) and incubated briefly before introduction to the gastric compartment [1].

2. Experimental Execution:

• Dosing: The dosage form (tablet/capsule) can be placed into the gastric compartment using a pharmaceutical stainless steel sinker to simulate swallowing [57].
• Gastric Phase (0-2h): Gastric secretion (electrolytes, pepsin, fungal lipase) is added. pH is dynamically controlled with HCl to follow a predetermined curve, typically starting around pH 5.0 and decreasing gradually [1]. Gastric emptying follows the curve described by Elashoff et al. (1982) [1].
• Intestinal Phase (0-6h): As chyme enters the duodenal/small intestinal compartment, duodenal secretion (electrolytes, bile, pancreatin) is added. The pH is maintained at typical intestinal values (e.g., ~6.5) using sodium bicarbonate [1].
• Sampling: The bioaccessible fraction is defined as the compound that has passed the dialysis or filtration membrane (molecular weight cutoff ~10 kDa) [1] [9]. For TIM-1, additional samples can be taken from different intestinal compartments to obtain site-specific data [57].

3. Post-Experiment Analysis:

• Samples are analyzed using validated analytical methods (e.g., HPLC/UHPLC).
• Bioaccessibility is calculated as the cumulative amount of drug collected from the dialysate/filtrate over time, expressed as a percentage of the administered dose [57] [9].

The workflow for this protocol is summarized below:

Fed State Bioaccessibility Workflow

The Scientist's Toolkit: Essential Research Reagents

The physiological relevance of TIM experiments depends on the use of carefully designed, biorelevant reagents. The table below lists key solutions used in the protocols.

Table 3: Key Reagent Solutions for TIM Experiments

Reagent Solution	Composition	Physiological Function
Artificial Saliva	Electrolytes, α-amylase [1]	Initiates oral digestion of starch and moistens the bolus.
Gastric Secretion	Electrolytes, pepsin, fungal lipase (e.g., F-AP 15) [1]	Simulates gastric digestion, breaking down proteins and lipids.
Duodenal Secretion	Electrolytes, bile salts, pancreatin [1]	Neutralizes gastric acid and provides key enzymes (e.g., pancreatic lipase, proteases) and bile for lipid solubilization.
Sodium Bicarbonate Solution	Aqueous NaHCO₃ [1]	Used for precise pH control in the intestinal compartments.
High-Fat Meal	Macro-nutrients meeting regulatory guidelines (e.g., ~1000 kcal, 50% from fat) [14]	Standardized meal to simulate fed state conditions and assess food effects.

Application Guidance and Decision Framework

Choosing between TIM-1 and tiny-TIM is a strategic decision that depends on the research question, the formulation type, and the required level of detail.

Select TIM-1 for:

• Modified Release (MR) Formulations: Its multi-compartment design is ideal for studying site-specific release and absorption in different regions of the small intestine [57].
• Detailed Mechanistic Studies: When a deep understanding of dissolution, precipitation, and re-dissolution events at specific intestinal sites is required [8] [57].
• Comprehensive Food Effect Studies: The ability to track formulation behavior throughout the entire GI transit provides a complete picture of food-related interactions [57].

Select Tiny-TIM for:

• Immediate Release (IR) Formulations: It provides a high predictive quality for bioavailability, often with a better prediction of tmax for IR products, and at a higher throughput [57].
• Formulation Screening: Its simplified operation and faster turnaround make it suitable for ranking formulations in early development [57] [14].
• Studies on Specific Lumenal Processes: When the focus is on dissolution and solubilization without the need for regional data, such as assessing the impact of acid-reducing agents [14] [9].

For a quantitative prediction of human pharmacokinetics, the bioaccessibility data generated by either system can be used as input for Physiologically Based Pharmacokinetic (PBPK) modeling [8] [9]. This integrated approach can further enhance the translation of in vitro results to in vivo outcomes.

TIM-1 and tiny-TIM are both powerful, physiologically relevant tools that offer high predictive quality for the bioaccessibility of orally administered drugs. TIM-1 is the system of choice for detailed, mechanistic studies on complex formulations like MR products, providing unparalleled insight into regional GI behavior. In contrast, tiny-TIM offers a robust, higher-throughput alternative that is particularly well-suited for screening and optimizing IR formulations. The choice of system should be guided by the specific research objectives, balancing the need for mechanistic detail against throughput and efficiency in the drug development pipeline.

Within the broader thesis on the application of the TNO Gastro-Intestinal Model (TIM) in bioaccessibility research, it is essential to contextualize its performance against other available in vitro systems. The accurate prediction of a substance's bioaccessibility—its release from a food or drug matrix and solubility in the gastrointestinal tract, making it available for absorption—is a cornerstone of nutritional and pharmaceutical development [9]. While simple static dissolution apparatuses serve a purpose for quality control, they often fail to establish reliable in vitro-in vivo correlations (IVIVC) because they inadequately represent dynamic human physiological conditions [10]. This has driven the development of more sophisticated dynamic models that better simulate the complex, changing environment of the human gut. This document provides a detailed benchmarking analysis and associated protocols for comparing the TIM system against other key model types: the Human Gastric Simulator (HGS), the Dynamic Gastric Model (DGM), and static systems.

The following table summarizes the core characteristics, advantages, and limitations of each model system, providing a baseline for their comparative evaluation.

Table 1: Overview and Benchmarking of In Vitro Gastrointestinal Models

Model Type	Key Characteristics	Applications in Bioaccessibility	Validation & Predictive Power	Inherent Limitations
Static Systems [10]	- Simple, single-compartment vessels.- Fixed pH and enzyme concentrations.- No peristalsis or transit.	- Quality control (e.g., USP apparatus I/II).- Preliminary, low-cost screening.	- Often poor IVIVC, especially for low-solubility compounds.- Can misguide formulation development.	- Lacks physiological dynamics (pH, secretion, emptying).- Oversimplifies food-drug interactions.
Dynamic Gastric Model (DGM) [10]	- Single-chamber stomach model.- Simulates antral motility via rhythmic pressure/piston movement.- Can assess capsule rupture time and disintegration.	- Studying initial drug release and food disintegration in the gastric phase.- Useful for solid dosage forms and food digestion.	- Results for capsule rupture time consistent with in vivo data.	- Does not include intestinal compartments.- Limited ability to predict overall bioaccessibility for absorption.
Human Gastric Simulator (HGS) [10]	- Designed to mimic the unique morphology and peristalsis of the human stomach.- Focuses on realistic physical breakdown.	- Investigation of gastric emptying of real foods (e.g., cooked rice, beef, milk).- Studying the impact of gastric processing on drug release from complex food matrices.	- Validated against in vivo gastric emptying data for various foods.- Used in pharmaceutical research (e.g., probiotic metabolism).	- Primarily focused on the gastric phase; requires coupling with an intestinal model for full bioaccessibility.
TIM Systems [9] [10]	- Multi-compartmental (stomach, small intestine, often colon).- Computer-controlled dynamic parameters (pH, secretions, emptying).- Dialysis/filtration units to measure bioaccessible fraction.	- Full transit, digestibility, and bioaccessibility of nutrients/drugs.- Simulation of fasted/fed states, age, co-medication.- Studied fat, cholesterol, carotenoids, infant formula, and drug release.	- High predictive quality for human bioavailability and plasma levels.- High predictive quality for human bioavailability and plasma levels.- Used as input for in silico modeling to predict pharmacokinetics.	- Technically complex and requires significant expertise.- Can overlook real morphological structures (addressed in newer TIMagc with J-shaped stomach).

The data from these models, particularly the quantitative bioaccessibility outputs, can be used as input for in silico kinetic modeling to predict systemic exposure and plasma concentrations, bridging the gap between in vitro experiments and clinical outcomes [9] [10]. The workflow below illustrates this integrated approach.

Integrated Workflow for Bioaccessibility and Pharmacokinetic Prediction

Experimental Protocols for Comparative Studies

Protocol 1: Assessing Food Effect on Drug Bioaccessibility Using a Dynamic System

This protocol is adapted from a case study on metformin hydrochloride tablets conducted in a DHSI-IV system [10]. It can be adapted for other dynamic models like TIM.

1.0 Objective: To evaluate the impact of a high-fat meal on the release and bioaccessibility of immediate-release (IR) and sustained-release (SR) oral solid dosage forms under simulated fasted and fed states.

2.0 Research Reagent Solutions: Table 2: Essential Reagents for Dynamic GI Experiments

Reagent Solution	Function	Example Composition / Notes
Simulated Gastric Fluid (SGF)	Mimics stomach environment for dissolution and digestion.	Pepsin in electrolyte solution, pH initially ~1.6-2.0 [10].
Simulated Intestinal Fluid (SIF)	Mimics small intestine environment for further digestion and solubilization.	Pancreatin and bile salts in electrolyte solution, pH ~6.5-7.5 [10].
High-Fat Meal Model	Represents the fed state physiological conditions.	Ensure liquid meal or other standardized model; affects gastric pH and emptying [10].
Metformin HCl Tablets	Model BCS Class III drug for protocol validation.	Use both IR and SR formulations for comparative analysis [10].

3.0 Methodology:

• 3.1 System Setup: Initialize the dynamic gastrointestinal system (e.g., TIM-1, DHSI-IV). Configure computer-controlled parameters for gastric emptying and intestinal transit according to established physiological profiles for fasted and fed states.
• 3.2 Fasted State Experiment:
  • Introduce the dosage form (IR or SR tablet) into the gastric compartment with fasted-state SGF.
  • Monitor and adjust pH dynamically to simulate in vivo profiles (e.g., from pH 1.6 to ~5 over 2 hours).
  • Collect intestinal digest from the distal ileum compartment over time. Filter samples (e.g., 0.15 µm) to obtain the bioaccessible fraction.
• 3.3 Fed State Experiment:
  • Mix the dosage form with the high-fat meal model before introducing it to the gastric compartment.
  • Use fed-state SGF and adjust the gastric emptying curve to a slower, lag-phase profile.
  • Collect and filter intestinal digest as in 3.2.
• 3.4 Analytical Measurement: Quantify the drug concentration in the filtered intestinal digest using a validated method (e.g., HPLC-UV). Calculate the cumulative percentage of drug released and the total bioaccessible fraction.

4.0 Data Analysis:

• Plot release curves (cumulative release % vs. time) for both formulations under fasted and fed states.
• Calculate key parameters: bioaccessible fraction (%), and for IR tablets, note the fed/fasted ratio (e.g., 76.2% for IR, 95.5% for SR in the case study) [10].
• Use a convolution-based approach to convert in vitro bioaccessibility data into predicted plasma concentration curves for comparison with human pharmacokinetic data.

Protocol 2: Validating Model Predictive Power againstIn VivoData

1.0 Objective: To validate the predictive quality of the TIM system by comparing in vitro bioaccessibility results with human bioavailability data.

2.0 Methodology:

• 2.1 In Vitro Phase: Conduct bioaccessibility studies using the TIM system as described in Protocol 1 and literature [9]. The system should include dialysis membranes to separate the absorbable fraction.
• 2.2 Data Integration: Use the generated bioaccessibility-time profile as input for a commercial or custom in silico model. This model incorporates published kinetic data on distribution, metabolism, and excretion.
• 2.3 Prediction & Comparison: The in silico model outputs a predicted plasma concentration-time profile. Compare the predicted pharmacokinetic parameters (C~max~, T~max~, AUC) with values observed in human clinical studies [9].

3.0 Validation: A high predictive quality is demonstrated when the predicted PK parameters show good agreement with human data, confirming the model's utility in replacing animal studies and increasing the success rate of human trials [9]. The following diagram outlines the validation pathway for a model like TIM.

TIM Model Validation Pathway

The TNO Gastro-Intestinal Model (TIM) systems represent a category of computer-controlled, dynamic in vitro models that closely simulate human gastrointestinal conditions. These systems are critically important in pharmaceutical research for predicting the bioaccessibility of Active Pharmaceutical Ingredients (APIs)—the fraction dissolved and available for absorption—thereby providing highly predictive information for human in vivo performance [9]. For drug development professionals, TIM systems offer a powerful tool to overcome the challenges of poorly soluble new chemical entities and complex formulations, accurately forecasting performance under various physiological conditions such as fasted and fed states, thereby reducing the need for animal studies and increasing the success rate of subsequent human trials [9] [57].

Validated Predictive Performance of TIM Systems

Extensive validation studies against human clinical data demonstrate that TIM systems achieve high predictive accuracy for API bioaccessibility and food effects.

TIM-1 and tiny-TIM for Upper GI Tract Simulation

Table 1: Predictive Performance of TIM-1 and tiny-TIM for API Bioaccessibility

API / Formulation	TIM System	Condition	TIM Bioaccessibility Finding	Correlation with Human Data
Ciprofloxacin (IR) [57]	TIM-1 & tiny-TIM	Fasted	Higher & earlier bioaccessibility from IR vs. MR	Matched human plasma tmax profile; correctly predicted absence of food effect
Nifedipine (IR vs. MR) [57]	TIM-1 & tiny-TIM	Fasted	Higher bioaccessibility from IR vs. MR	Consistent with human pharmacokinetic data
Posaconazole [57]	TIM-1 & tiny-TIM	Fed vs. Fasted	Presence of a significant positive food effect	Correctly predicted increased bioavailability with food, as seen in clinical studies
Fenofibrate (Nano vs. Micro) [57]	TIM-1 & tiny-TIM	Fasted	Higher bioaccessibility from nano-formulation	Agreement with human data showing superior performance of nanosuspensions

A systematic evaluation of TIM-1 versus clinical data demonstrated a correct in vivo rank order prediction of 84% for AUC and 79% for Cmax across nine different APIs in 19 immediate-release (IR) formulations [57]. Both TIM-1 and its simplified counterpart, tiny-TIM, effectively predicted the absence (e.g., Ciprofloxacin) or presence (e.g., Posaconazole) of food effects in line with human data [57]. The tiny-TIM model, in particular, provides a higher-throughput option while maintaining predictive power, especially for IR formulations [57].

Comprehensive Food Effect Prediction with tiny-TIM

Table 2: Summary of tiny-TIM Food Effect Predictions for a Diverse Drug Panel

Compound Class	Example Drugs	Number of Drugs Tested	tiny-TIM Prediction Accuracy
BCS Class I-IV	Amoxicillin, Aspirin, Atenolol, Atazanavir, Acyclovir, Pravastatin, Ibuprofen, Metformin [59]	>20	Good agreement with reported human data for all BCS classes
Acidic Drugs & Salts	Ibuprofen, Ibuprofen Liquid Fill, Ibuprofen Fast Release [59]	Multiple	Successfully captured food effect trends related to formulation
Basic Drugs & Salts	Atazanavir, Metformin [59]	Multiple	Accurately predicted positive food effect for Metformin

A broad evaluation of tiny-TIM with over 20 marketed or development drugs spanning all Biopharmaceutics Classification System (BCS) classes confirmed its robust predictive capability for food effects [59] [60]. The system successfully captures the complex interplay between API physicochemical properties, formulation characteristics, and dynamic GI physiology under fed and fasted conditions. For instance, the dynamic pH environment in tiny-TIM's gastric compartment—where pH gradually decreases after a meal, mimicking the in vivo scenario—is crucial for accurately predicting the dissolution and subsequent absorption of ionizable drugs [59].

Figure 1: Integrated TIM and in silico workflow for predicting human drug absorption.

TIM-2 Model for Colonic Processing and Microbiome Studies

The TIM-2 model simulates the proximal colon and is a key tool for studying the interaction of APIs, nutrients, and the gut microbiome. This dynamic model incorporates a complex, human-derived microbiota, peristaltic movements, pH control (~5.8), and a unique dialysis system that removes microbial metabolites, thereby maintaining a metabolically active microbiota similar to the in vivo density [61]. A recent advancement, the TIM-2muc model, incorporates a physiologically relevant mucus layer (Gut3beads), enabling simultaneous study of both the luminal microbiota (LM) and the mucosa-associated microbiota (MAM) [62]. This is a significant innovation as the MAM is distinct in composition and function from the LM and plays a critical role in gut health, immune function, and potentially in the metabolism of orally administered drugs [62]. Validation studies have shown that TIM-2muc successfully replicates the distinct microbial communities found in the luminal and mucosal niches in vivo, including higher levels of Bacteroidetes, Actinobacteria, and Proteobacteria in the MAM [62].

Detailed Experimental Protocols

Standard Protocol for Food Effect Assessment Using tiny-TIM

This protocol outlines the procedure for evaluating the effect of food on drug bioaccessibility, adapted from studies validating the model against human data [57] [59].

I. Pre-Experiment Setup

• System Preparation: Clean and calibrate the tiny-TIM system. Ensure the temperature is maintained at 37°C.
• Digestive Fluids: Prepare simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) according to standardized recipes. SIF typically includes pancreatin and bile salts [57] [59].
• Meal Preparation:
  • Fasted State: Typically, a simple aqueous solution or fasted-state simulated gastric fluid.
  • Fed State: Use a standardized meal. A common example is the FDA-standard high-fat meal (e.g., ~800-1000 calories, with ~50% from fat) or a nutrient-defined liquid meal like Ensure Plus [59].

II. Experimental Run

• Initial Loading: Place the meal (or fasted-state solution) into the advanced gastric compartment.
• Dosing: Introduce the drug product into the gastric compartment. Tablets/capsules are often placed in a pharmaceutical sinker to simulate swallowing without immediate disintegration [57].
• Dynamic Simulation:
  • Gastric Phase: Initiate the secretion of SGF and gastric acid. The pH is not held constant but is allowed to gradually decrease from ~6 to ~1.5-2 over 1-2 hours, mimicking physiological acid secretion [59].
  • Gastric Emptying: Empty the gastric content into the single small intestinal compartment in a gradual, physiologically realistic pattern (e.g., using first-order kinetics).
  • Intestinal Phase: As gastric content empties, simultaneously add SIF containing pancreatin and bile to the intestinal compartment. Maintain intestinal pH at ~6.5-7.5.
• Sampling: Continuously collect the filtrate from the hollow fiber membrane filter compartment, which represents the bioaccessible fraction (dissolved API available for absorption). Take samples at predefined time points over 3-6 hours for analysis [57] [59].

III. Data Analysis

• Quantify the API concentration in the collected filtrate samples using a validated analytical method (e.g., HPLC-UV/MS).
• Calculate the cumulative bioaccessibility profile over time.
• Compare the bioaccessibility profiles (e.g., AUC, Cmax, tmax) under fasted and fed states to determine the food effect [57].

Protocol for Studying Drug-Microbiome Interaction Using TIM-2

This protocol describes the use of the TIM-2 system to investigate the effect of a drug on the gut microbiota or the microbial metabolism of a drug [62] [61].

I. System Inoculation and Stabilization

• Inoculum Preparation: Pool fecal samples from several healthy human donors. Process the material under anaerobic conditions to preserve the viability of obligate anaerobes.
• Loading: Introduce the fecal microbiota preparation into the TIM-2 system.
• Stabilization Period: Circulate a standard nutrient medium for 16-24 hours to allow the microbial community to stabilize and reach a metabolic steady-state. Monitor Short-Chain Fatty Acid (SCFA) production to confirm stability [61].

II. Intervention and Sampling

• Dosing: Add the drug compound or a test formulation to the system. A control run without the drug should be performed in parallel.
• Dynamic Operation: Run the system for up to 72 hours with continuous peristaltic mixing and removal of microbial metabolites via the dialysis system.
• Sampling:
  • Luminal Content: Sample from the main compartment to analyze the luminal microbiota.
  • Mucus-Associated Microbiota (if using TIM-2muc): Separate the Gut3beads from the luminal content to analyze the MAM separately [62].
  • Dialysate: Collect the dialysate to quantify microbial metabolites (e.g., SCFAs, specific drug metabolites) [61].

III. Endpoint Analysis

• Microbial Analysis: Use 16S rRNA gene sequencing to profile the composition of the LM and MAM. Quantitative PCR can be used for specific taxa.
• Metabolomic Analysis: Analyze SCFAs (acetate, propionate, butyrate) and other relevant metabolites in the dialysate via GC-MS or LC-MS.
• Drug Analysis: Measure the concentration of the parent drug and potential microbial metabolites in the lumen and dialysate.

The Scientist's Toolkit: Essential Research Reagent Solutions

Table 3: Key Reagents and Materials for TIM Experiments

Item	Function / Purpose	Composition / Specification
Simulated Gastric Fluid (SGF)	Mimics the chemical environment of the stomach for dissolution and initial digestion.	Contains pepsin, sodium chloride; pH is dynamically adjusted from ~6 down to 1.5-2.0 [57] [59].
Simulated Intestinal Fluid (SIF)	Mimics the environment of the small intestine for further digestion and solubilization.	Contains pancreatin (source of amylase, protease, lipase) and bile salts (e.g., porcine bile extract) [57] [59].
Standardized Meals	To simulate fed state conditions for food effect studies.	FDA high-fat meal or defined liquid meals like Ensure Plus [59].
Hollow Fiber Membrane	Represents the intestinal barrier for absorption; filters the bioaccessible fraction.	Semipermeable membrane with a specific molecular weight cutoff [57].
Gut3beads (for TIM-2muc)	Provides a physiologically relevant mucus interface for studying mucosa-associated microbiota.	A synthetic matrix that chemically and structurally mimics native human mucus [62].
Fecal Microbiota Inoculum	Provides a complex, human-relevant microbial community for TIM-2 studies.	Pooled and processed fecal material from multiple healthy donors, prepared anaerobically [61].

The body of evidence confirms that TIM gastrointestinal models are highly predictive tools for human bioaccessibility and food effects. The TIM-1 and tiny-TIM systems successfully forecast the in vivo performance of diverse APIs and formulations in the upper GI tract, while the TIM-2 and advanced TIM-2muc models provide unique insights into colonic processing and drug-microbiome interactions. The integration of bioaccessibility data from these validated in vitro systems with in silico modeling platforms creates a powerful, predictive toolkit that can significantly de-risk pharmaceutical development, reduce reliance on animal studies, and increase the probability of success in human clinical trials [9] [8].

Within bioaccessibility research, the TNO Intestinal Model (TIM) systems represent a sophisticated class of in vitro dynamic simulators of the human gastrointestinal (GI) tract. These systems are engineered to replicate the complex physiological processes of digestion under highly controlled conditions, offering a powerful alternative to traditional animal and human trials [21]. The drive to adopt such alternatives is fueled by a convergence of ethical imperatives, regulatory evolution, and scientific necessity. Growing ethical concerns and new regulatory frameworks, such as the U.S. Food and Drug Administration's move away from mandatory animal testing, are accelerating this transition [63]. Furthermore, the scientific limitations of animal models, including interspecies differences in anatomy, physiology, and drug response, often compromise the clinical translatability of research findings [63] [64]. TIM systems are designed to bridge this translational gap by providing human-relevant data on digestibility, nutrient release, and active compound absorption, thereby enabling more predictive and efficient development of pharmaceuticals and functional foods [21].

TIM System Specifications and Comparative Analysis

The TIM platform comprises several integrated systems, each simulating specific segments of the GI tract. The core systems include TIM-1 (stomach and small intestine), TIM-2 (large intestine), and tiny-TIM (a simplified, miniaturized system) [21]. A key advancement is the TIM-2muc model, which incorporates a physiologically relevant mucus layer (Gut3beads) that enables simultaneous study of luminal and mucosa-associated microbiota, crucial for understanding gut health and drug-microbiome interactions [62].

The following table summarizes the key operational parameters of these systems, illustrating their ability to mimic human physiology.

Table 1: Key Specifications of TIM Systems

System Parameter	TIM-1 & tiny-TIM	TIM-2 / TIM-2muc	Physiological Basis
Temperature Control	37°C	37°C	Human body temperature
pH Control	Real-time monitoring & adjustment	Real-time monitoring & adjustment	Fed/fasted state conditions
Gastric Motility	Water pressure on flexible membranes	Peristaltic mixing	Mimics antral contraction waves
Gastric Emptying	Computer-controlled emptying	N/A	Replicates housekeeper waves
Secretions	Programmable addition of enzymes, bile	Metabolite removal via dialysis	Simulates pancreatic, gastric, biliary output
Mucus Layer	N/A	Integrated (TIM-2muc)	Provides interface for mucosa-associated microbes

The design of these systems allows for significant operational flexibility. The stomach compartment in TIM-1 is a flexible tube surrounded by a water jacket; modulated water pressure creates peristaltic-like contractions that mix and break down food, with measured pressures ranging from 2 to 18 mm Hg, which are validated against human in vivo data [21]. The tiny-TIM system offers a compromise between complexity and practicality, incorporating gradual acidification and enzyme addition in the gastric phase while using smaller volumes, making it ideal for testing expensive or scarce compounds like new drug candidates [18] [21].

Quantitative Cost-Benefit Analysis

A rigorous cost-benefit analysis must consider both tangible and intangible factors. The following table provides a structured comparison between TIM systems and traditional testing methodologies.

Table 2: Cost-Benefit Analysis: TIM vs. Traditional Models

Factor	TIM Systems	Animal Trials	Human Trials
Direct Financial Cost	Lower per experiment; high initial capital investment	Very high (housing, care, ethical oversight)	Extremely high (recruitment, clinics, oversight)
Experiment Duration	Rapid setup and results (hours/days)	Long (months/years for disease models)	Very long (months/years for longitudinal studies)
Ethical Considerations	Non-animal method; aligns with 3Rs	Major ethical concerns and oversight	Stringent ethical oversight for safety
Data Control & Sampling	High precision; easy, continuous sampling	Limited by animal welfare	Highly restricted by participant burden and safety
Human Relevance	High (uses human cells/fluids)	Variable due to interspecies differences [64]	Directly relevant
Regulatory Acceptance	Growing acceptance for specific endpoints [63]	Traditional "gold standard"	Ultimate standard for efficacy and safety
Throughput	Medium to High (can be parallelized)	Low	Very Low
Key Benefit	Predictive, human-relevant, controlled data	Whole-system biology	Clinically translatable outcomes
Key Limitation	Simplified anatomy and lack of full systemic response	Poor clinical translatability in many cases [63]	Prohibitively expensive and complex

The benefits of TIM systems extend beyond direct cost savings. By providing highly controlled, human-relevant data early in the development pipeline, they help de-risk projects, reducing the likelihood of late-stage, costly failures in human clinical trials. This aligns with the "fail early, fail cheaply" paradigm, which is critical in industries like pharmaceuticals where late-stage attrition rates are high [65] [63].

Detailed Experimental Protocols

Protocol 1: General Bioaccessibility Assessment using tiny-TIM

This protocol outlines the steps to assess the bioaccessibility of a bioactive compound or a poorly soluble drug using the tiny-TIM system.

Research Reagent Solutions:

• Simulated Gastric Fluid (SGF): Contains pepsin. Function: Mimics the chemical environment of the stomach for protein hydrolysis.
• Simulated Intestinal Fluid (SIF): Contains pancreatin and bile salts. Function: Replicates the small intestine environment for lipid emulsification and nutrient absorption.
• Dialysis Membrane: (In some TIM setups). Function: Allows passive removal of small molecules and water, simulating absorption.
• Gut3beads (for TIM-2muc): A synthetic mucus matrix. Function: Provides a physiologically accurate interface for studying mucosa-associated microbiota [62].

Workflow Diagram:

Methodology:

• System Pre-conditioning: Set up the tiny-TIM system. Flush all lines with appropriate buffers. Set temperature to 37°C and initialize pH probes.
• Oral Bolus Introduction: Mix the test compound with a standardized meal or vehicle and simulated salivary fluid. Introduce this bolus into the gastric compartment.
• Semi-Dynamic Gastric Phase: Initiate the gastric digestion phase. Key dynamic parameters include:
  • Gradual Acidification: Program the system to lower the pH from the initial meal pH (e.g., ~5) to a fasted state pH (~1.5-2) over a period of 1-2 hours, mimicking in vivo conditions [18] [21].
  • Gradual Enzyme Addition: SGF containing pepsin is added at a controlled rate throughout the gastric phase.
  • Gastric Emptying: The semi-dynamic protocol simulates gastric emptying by transferring small volumes of the gastric chyme to the intestinal compartment at regular intervals [18].
• Intestinal Phase: As the gastric chyme enters the intestinal compartment, maintain the pH at ~6.5-7. Start the continuous addition of SIF containing pancreatin and bile salts. The intestinal phase is typically static, with a fixed volume and incubation time of 2 hours.
• Sample Collection: Collect samples from the intestinal compartment at defined time points. Centrifuge to separate the aqueous phase (containing the bioaccessible compound) from the pellet (undigested material). Analyze the aqueous phase using appropriate analytical techniques (e.g., HPLC, MS) to quantify the released compound.

Protocol 2: Microbiome Interaction Studies using TIM-2muc

This protocol leverages the advanced TIM-2muc model to study the interaction between a compound and the gut microbiome.

Workflow Diagram:

Methodology:

• System Inoculation: The TIM-2muc system is inoculated with a standardized human fecal microbiota sample. The system includes the Gut3beads mucus matrix.
• Stabilization: The microbiome is allowed to stabilize for a period of over 72 hours under conditions that mimic the colon (e.g., pH, temperature, anoxia). The system's dialysis membrane removes fermentation metabolites to maintain a healthy microbial community.
• Dosing: The test compound (e.g., a drug, prebiotic, or functional food ingredient) is introduced into the system via a standardized medium.
• Simulation Run: The experiment runs for a predetermined period (typically 24-72 hours), with continuous monitoring of environmental parameters.
• Dual Sampling: Samples are collected separately from the lumen (Luminal Microbiome, LM) and from the mucus beads (Mucosa-Associated Microbiome, MAM). This allows for distinct analysis of these two microbial niches [62].
• Analysis:
  • Microbial Composition: Analyze LM and MAM samples via 16S rRNA gene sequencing to assess shifts in microbial community structure.
  • Metabolomics: Measure short-chain fatty acid (SCFA) production (e.g., butyrate, acetate, propionate) as a key functional output of microbial activity. TIM-2muc has been shown to produce a higher proportion of butyrate, a marker of colonic health [62].

Validation and Case Studies

The predictive power of TIM systems is underpinned by rigorous validation against human data. A key study compared the composition and solubilizing capacity of intestinal fluids from tiny-TIM (TIF) with human intestinal fluids (HIF). While some differences were noted (e.g., higher bile salt levels in fasted-state TIF), the model was found to be highly biorelevant, particularly in simulating the fed state and predicting the solubility of poorly soluble drugs [42].

In another validation, the Dynamic Gastric Model (DGM) was tested using agar gel beads of known fracture strength. The results demonstrated a disintegration profile that closely matched data from human in vivo trials, unlike simple magnetic stirring systems which only caused surface erosion. This highlights the critical importance of accurately simulating mechanical forces in digestion models [21].

Case studies demonstrate TIM's practical utility:

• Pharmaceutical Development: TIM systems are used to study the food effect on drug absorption, the release profile of oral formulations, and the potential impact of drugs on the gut microbiome, providing data that supports Investigational New Drug (IND) applications [42] [62].
• Nutritional Science: TIM has been employed to assess the bioaccessibility of micronutrients from fortified foods, the efficacy of probiotic strains, and the prebiotic potential of dietary fibers, guiding the development of evidence-based functional foods [21].

The Scientist's Toolkit

Table 3: Essential Research Reagent Solutions for TIM Experiments

Reagent / Material	Function	Key Considerations
Simulated Salivary Fluid (SSF)	Initiates starch hydrolysis; forms bolus.	Contains electrolytes and α-amylase.
Simulated Gastric Fluid (SGF)	Provides acidic environment and proteolytic activity.	Contains pepsin; pH is dynamically controlled.
Simulated Intestinal Fluid (SIF)	Emulsifies fats and continues nutrient digestion.	Contains pancreatin (mix of enzymes) and bile salts.
Dialysis Membrane	Simulates passive absorption in the small intestine.	Pore size determines molecular weight cut-off.
Gut3beads	Mimics the colonic mucus layer for microbiome studies.	Essential for distinguishing LM and MAM [62].
Fecal Inoculum	Provides a complex, human-relevant microbial community for colon models.	Must be sourced from healthy donors and processed promptly.

TIM gastrointestinal models present a compelling alternative to animal and human trials for bioaccessibility research. A thorough cost-benefit analysis reveals significant advantages in terms of ethical compliance, operational control, and financial efficiency, without compromising human relevance. While not replacing human trials for final safety and efficacy confirmation, TIM systems drastically improve the predictability and success rate of the development pipeline. The ongoing refinement of these systems, such as the incorporation of a mucus layer in TIM-2muc, continues to enhance their physiological accuracy. As regulatory frameworks increasingly accept human-relevant data from advanced in vitro models, the adoption of TIM technology is poised to accelerate, fostering more efficient, ethical, and translatable scientific research.

Conclusion

The TIM gastrointestinal model stands as a validated and highly predictive tool for bioaccessibility assessment, bridging the gap between traditional in vitro tests and complex human trials. Its dynamic, physiologically relevant environment allows for accurate prediction of drug performance under various conditions, including the critical impact of food. While considerations around model complexity and fluid composition exist, its strengths in providing human-relevant data are undeniable. The future of TIM lies in its deeper integration with in silico modeling and cellular absorption assays, creating a powerful, holistic prediction platform for oral drug and nutrient development. This synergy promises to further reduce reliance on animal studies, de-risk clinical trials, and accelerate the delivery of effective therapeutics to patients, solidifying TIM's role as a cornerstone of modern biopharmaceutical research.

References

• 1. The TNO Gastro-Intestinal Model (TIM) - NCBI - NIH [https://www.ncbi.nlm.nih.gov/books/NBK500162/]
• 2. TNO intestinal model [https://en.wikipedia.org/wiki/TNO_intestinal_model]
• 3. Application of in vitro bioaccessibility and bioavailability ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3429087/]
• 4. Results from a Validated in vitro Gastrointestinal Model ... [https://esmed.org/MRA/mra/article/view/3136/1000]
• 5. In vitro gastrointestinal model (TIM) with predictive power, ... [https://www.sciencedirect.com/science/article/abs/pii/S0378517313006790]
• 6. Comparison of Nitrogen Bioaccessibility from Salmon and ... [https://ffhdj.com/index.php/ffhd/article/view/10]
• 7. [PDF] The TNO Gastro-Intestinal Model (TIM) [https://www.semanticscholar.org/paper/The-TNO-Gastro-Intestinal-Model-(TIM)-Minekus/2e8a3f690fd2975c519fb23957206c04e5af863e]
• 8. Digitalizing the TIM-1 Model using Computational ... [https://pubmed.ncbi.nlm.nih.gov/37878746/]
• 9. Results from a Validated in vitro Gastrointestinal Model ... [https://esmed.org/MRA/mra/article/view/3136]
• 10. In vitro release and bioaccessibility of oral solid ... [https://www.sciencedirect.com/science/article/abs/pii/S0378517324001030]
• 11. Computer modeling of digestive processes in the alimentary ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11007706/]
• 12. Quantitative analysis of gastrointestinal fluid absorption ... [https://www.nature.com/articles/s41598-023-44742-y]
• 13. In Silico Modelling of Physiologically Based Intestinal ... [https://www.sciencedirect.com/science/article/abs/pii/S026087742500398X]
• 14. Application of tiny-TIM as a mechanistic tool to investigate ... [https://www.sciencedirect.com/science/article/pii/S0928098722000501]
• 15. Results from a Validated in vitro Gastrointestinal Model ... [https://esmed.org/MRA/index.php/mra/article/view/3136]
• 16. Colour contrast [https://goodpractices.design/articles/colour-contrast]
• 17. Journal of Pharmaceutical Sciences [https://www.sciencedirect.com/science/article/abs/pii/S0022354921005505]
• 18. A miniaturised semi-dynamic in-vitro model of human ... [https://www.nature.com/articles/s41598-024-54612-w]
• 19. Evaluation of bioaccessibility and bioavailability of dietary ... [https://www.sciencedirect.com/science/article/abs/pii/S2212429224018595]
• 20. Boiling Outperforms Other Thermal Treatments in ... [https://www.sciencedirect.com/science/article/abs/pii/S2212429225015767]
• 21. Progress and challenges in designing dynamic in vitro ... [https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2024.1399534/full]
• 22. A review of in-vitro digestibility models on diverse foods ... [https://link.springer.com/article/10.1007/s44187-025-00454-y]
• 23. Evaluation of bioaccessibility of bioactive compounds in ... [https://www.nature.com/articles/s41598-025-26034-9]
• 24. Extraction Processes, Bioaccessibility, Antioxidant ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12057547/]
• 25. Foundations of gastrointestinal-based drug delivery and future ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12053541/]
• 26. ORAL DOSAGE FORMS - The Future of Oral Dosage [https://drug-dev.com/oral-dosage-forms-the-future-of-oral-dosage-innovations-challenges-the-path-forward-in-2025/]
• 27. an in vitro digestion approach [https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2025.1666391/full]
• 28. Industry Leaders Weigh in on the Future of Oral Solid Dose [https://www.tabletscapsules.com/3641-Technical-Articles/617375-2025-Predictions-Industry-Leaders-Weigh-in-on-the-Future-of-Oral-Solid-Dose/]
• 29. Food effects on gastrointestinal physiology and drug ... [https://www.sciencedirect.com/science/article/abs/pii/S1347436722000453]
• 30. Food, Eating, and the Gastrointestinal Tract - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC7231022/]
• 31. Evaluation of two dynamic in vitro models simulating fasted and fed... [https://pubmed.ncbi.nlm.nih.gov/26688035/]
• 32. Influence of Diet on the Bioaccessibility of Active ... [https://www.mdpi.com/1420-3049/30/22/4429]
• 33. Novel Strategies for the Formulation of Poorly Water ... [https://www.mdpi.com/1424-8247/18/8/1089]
• 34. New Whitepaper "Bioavailability Enhancement Strategies ... [https://www.aenova-group.com/en/news-events/news/22-04-2025-new-whitepaper-on-bioavailability-enhancement-strategies-for-poorly-soluble-drugs]
• 35. Innovative Pharmaceutical Formulation Strategies to ... [https://www.upm-inc.com/innovative-approaches-in-pharmaceutical-formulation-for-improving-drug-bioavailability]
• 36. Avrupa Bilim ve Teknoloji Dergisi » Submission » TIM Systems... [https://dergipark.org.tr/en/pub/ejosat/issue/40225/479506]
• 37. An emerging formulation strategy for poorly water-soluble ... [https://www.sciencedirect.com/science/article/abs/pii/S1359644624000084]
• 38. Bioaccessibility and bioactive potential of different ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10415696/]
• 39. Assessment of protein and phospholipid bioaccessibility in ... [https://www.sciencedirect.com/science/article/pii/S0963996924006768]
• 40. Beyond Seasoning Nutrients Bioactive Ingredients and ... [https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2025.1597788/full]
• 41. Experimental Protocols Used to Mimic Gastrointestinal ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11314321/]
• 42. Tiny-TIM intestinal fluids versus human ... [https://www.sciencedirect.com/science/article/pii/S0928098725001496]
• 43. Gastrointestinal Bile Salt Concentrations in Healthy Adults ... [https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=39843813]
• 44. Bile salt induced aggregation and nanostructure formation ... [https://www.sciencedirect.com/science/article/abs/pii/S0268005X24012189]
• 45. Modelling and simulation as research tools in paediatric ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3082698/]
• 46. Influence of Diet on the Bioaccessibility of Active ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12655224/]
• 47. (PDF) Evaluation of two dynamic in vitro models simulating fasted and... [https://www.academia.edu/85237372/Evaluation_of_two_dynamic_in_vitro_models_simulating_fasted_and_fed_state_conditions_in_the_upper_gastrointestinal_tract_TIM_1_and_tiny_TIM_for_investigating_the_bioaccessibility_of_pharmaceutical_compounds_from_oral_dosage_forms]
• 48. Modelling and simulation: questions and answers [https://www.ema.europa.eu/en/human-regulatory-overview/research-and-development/scientific-guidelines/clinical-pharmacology-pharmacokinetics/modelling-simulation-questions-answers]
• 49. Physiologically based pharmacokinetic (PBPK) modelling ... [https://www.sciencedirect.com/science/article/pii/S0928098723001264]
• 50. Absorption to Excretion: The Aging Body's Take on Drugs – ... [https://link.springer.com/article/10.1007/s40495-025-00425-y]
• 51. Utilizing Physiologically Based Pharmacokinetic Models to ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12034845/]
• 52. Mucin-Protected Caco-2 Assay to Study Drug Permeation in the Presence of Complex Biorelevant Media - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC9032137/]
• 53. Development of a Caco-2-based intestinal mucosal model ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11702969/]
• 54. Development of a Caco-2-based intestinal mucosal model to study intestinal barrier properties and bacteria-mucus interactions - PubMed [https://pubmed.ncbi.nlm.nih.gov/39714032/]
• 55. The bioaccessibility of eicosapentaenoic acid was higher ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3951535/]
• 56. Towards Prediction of In Vivo Intestinal Absorption Using a ... [https://www.sciencedirect.com/science/article/abs/pii/S0022354915325740]
• 57. Evaluation of two dynamic in vitro models simulating fasted ... [https://www.sciencedirect.com/science/article/abs/pii/S0378517315303938]
• 58. Nonclinical and Clinical Assessments of an Optimized Tablet ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12587387/]
• 59. Evaluating Utilization of Tiny-TIM to Assess the Effect of ... [https://www.sciencedirect.com/science/article/abs/pii/S0022354924000121]
• 60. Evaluating Utilization of Tiny-TIM to Assess the Effect ... [https://pubmed.ncbi.nlm.nih.gov/38266915/]
• 61. What is the TIM-2 system? An in-vitro model of the colon [https://solabianutrition.com/tim-2-a-validated-in-vitro-model-of-the-colon/]
• 62. InnoGI Technologies Unveils its Advanced Gut ... [https://www.microbiometimes.com/innogi-technologies-unveils-its-advanced-gut-microbiome-model-tim-2-by-incorporating-mucus/]
• 63. Replacing Animal Testing with Stem Cell-Organoids [https://pmc.ncbi.nlm.nih.gov/articles/PMC11319430/]
• 64. A Simulation-Based Comparison of Human, Porcine and ... [https://link.springer.com/article/10.1007/s13239-025-00803-z]
• 65. Non-Animal & Human-Relevant Research News: July 2025 [https://riseforanimals.org/news/sci-news-july-2025/]